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ABSTRACT:  Plasmodium parasites, the causative agents of malaria, have developed resistance 
to most of our current antimalarial therapies, including artemisinin combination therapies which 
are widely described as our last line of defense. Antimalarial agents with a novel mode of action 
are urgently required. Two Plasmodium falciparum aminopeptidases, PfAM1 and PfAM17, 
play crucial roles in the erythrocytic stage of infection, and have been validated as potential 
antimalarial targets. Using compoundbound crystal structures of both enzymes, we have used a 
structureguided approach to develop a novel series of inhibitors capable of potent inhibition of 
both PfAM1 and PfAM17 activity, and parasite growth in culture. Herein we describe the 
design, synthesis, and evaluation of a series of hydroxamic acidbased inhibitors, and 
demonstrate the compounds to be exciting new leads for the development of novel antimalarial 
therapeutics. 
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 INTRODUCTION 
Malaria, caused by parasites of the genus Plasmodium (of which Plasmodium falciparum, Pf, is 
the most lethal), is the world’s most prevalent parasitic disease. The spread of drugresistant 
parasites has rendered most of the current antimalarial treatments ineffective; consequently, 
prevention and treatment of malaria is becoming increasingly difficult. The most recent WHO 
World Malaria Report indicated that in 2012 alone, there were approximately 627,000 deaths 
from malaria. There is an urgent need for next generation antimalarial agents with novel modes 
of action.  
 During the symptomatic erythrocytic stage of Pf infection, parasites degrade 
haemoglobin into free amino acids.1, 2 These free amino acids are essential in a variety of critical 
processes; including parasite growth and development,2 protein synthesis, and maintenance of 
osmotic pressure within the infected red blood cell to prevent premature cell lysis.3 The final 
stage of haemoglobin digestion is mediated by metalloaminopeptidases (MAPs), which act to 
degrade small peptide fragments into free amino acids.4, 5 Inhibitors of these enzymes, thus 
represent attractive leads for the development of novel antimalarial therapeutic agents. Pf 
employs two neutral MAPs, PfAM1 and PfAM17. Both enzymes bear zinc bindingmotifs that 
have essential roles in both substrate and drug binding.6 
Inhibition of PfAM1 and PfAM17 has been shown to control both Pf laboratory and P. 
chabaudi chabaudi murine models of malaria,7, 8 and while potent inhibitors of either PfAM1 or 
PfAM17 have been identified,712 differences in the compound binding profiles of the enzymes 
meant that compound elaboration generally favored selectivity for one enzyme over the other. 
Previous work within our group identified ((4(1Hpyrazol1
yl)phenyl)(amino)methyl)phosphonic acid () (	) as a lead for the development of a dual 
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 inhibitor of both PfAM1 and PfAM17.13 Xray crystal structures of both enzymes in complex 
with  showed that the compound sits within the S1 pocket and coordinates the catalytic zinc 
ion/s through the aminophosphonate moiety.13 Although aminophosphonates are an established 
zincbinding group (ZBG), the phosphonic acid group would exist as a dianion at physiological 
pH (pKa 2.35 and ~6)
14 with potentially detrimental effects on membrane permeability. To 
generate dual PfAM1/PfAM17 inhibitors and address potential permeability issues conferred 
by the aminophosphonate moiety, we sought to employ an alternative ZBG. Hydroxamic acid 
based compounds that are capable of reaching the site of action within infected red blood cells 
and inhibiting PfAM1 have been described previously.10 Therefore, we replaced the phosphonic 
acid moiety of 1 with a hydroxamic acid to generate compounds that anticipated that installation 
of a hydroxamic acid group to replace the aminophosphonate phosphonic acid moiety of our 
previous series might confer improved inhibitory activity through improved coordination of the 
zinc ion. In addition, these compounds would have a more desirable permeability15, 16 and plasma 
stability profile.17 The hydroxamic acid group has been successfully used in inhibitors for several 
proteases, the most attractive being Tosedostat that shows promising efficacy in phase II clinical 
trials for patients with myelodysplastic syndrome and / or acute myeloid leukemia.18 Herein, we 
report the design, synthesis and inhibitory activity of novel carboxylic and hydroxamic acid 
derivatives of , leading to the discovery of compound 
 as a potent dual inhibitor of PfAM1/1
M17. Utilizing compound 
 as our new lead, we investigated structureactivity relationships 
(SAR) of this scaffold further, through a series of Nacyl derivatives in replacement of the N1Boc 
group. Finally, we demonstrate parasiticidal activity of our more potent dual inhibitors.  
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 RESULTS AND DISCUSSION 
	 It was envisaged that the desired αaminohydroxamic acid functionality could be 
accessed from the corresponding NBoc protected amino acid by first coupling with 
hydroxylamine before NBoc deprotection to unmask the final compound. Our initial strategy 
employed 2amino2(4bromophenyl)acetic acid as a starting material. NBocprotection of the 
amine and esterification of the carboxylic acid functionality were performed, prior to attempted 
Ullmanntype coupling with pyrazole under a variety of conditions,1921 none of which were 
successful (data not shown). Suspecting the presence of the bulky protected amine and 
carboxylic acid groups to be responsible for the failed coupling (either through a steric or 
potentially catalystchelating mechanism), an alternative strategy was devised, whereby Ullman
type Narylation of pyrazole could be carried out with a simple coupling partner, with subsequent 
installation of the αaminoacid functionality (Scheme 1). 
Literature precedent for the synthesis of 1(4(1Hpyrazol1yl)phenyl)ethan1one () in 
good to excellent yield is widespread.2233 In our hands, Narylation of pyrazole with 4’
iodoacetophenone () to give , was achieved in near quantitative yield using copper (I)
catalysed, ligand free Ullmantype coupling.21 Subsequent oxidation of  to the corresponding α
keto acidwas achieved with ease using SeO2/pyridine as the oxidation system.
34 Installation of 
the racemic amino acid system was carried out through initial reductive amination of the ketone 
moiety of  with N,Ndibenzylamine and Na(OAc)3BH under standard conditions.
35 The 
intermediate N,Ndibenzylprotected amino acid then underwent complete debenzylation in the 
presence of 10% Pd/C  in acidified methanol under a hydrogen atmosphere. Finally, NBoc 
protection of the HCl salt of the intermediate amino acid was carried out using Boc2O under 
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 mildly basic conditions. After purification, 2(4(1Hpyrazol1yl)phenyl)2((tert
butoxycarbonyl)amino)acetic acid , was obtained in 56 % yield over three steps. 
The hydroxamic acid ZBG has commonly been derived from the corresponding 
carboxylic acid precursor. In many cases the carboxylic acid group has also been found to 
possess the ability to bind zinc ions, albeit generally more weakly than the corresponding 
hydroxamic acid.15, 16 With this in mind, we chose to evaluate the inhibitory activity of both the 
carboxylic acid and hydroxamic acid derivatives of . N1Boc deprotection of  in the presence of 
4M HCl/dioxane and DCM afforded the HCl salt of the αaminocarboxylic acid derivative , in 
nearquantitative yield. In contrast the desired hydroxamic acid derivative was accessed via a 
twostep procedure. Initial conversion of NBocprotected αaminocarboxylic acid  to the 
corresponding NBocprotected αaminohydroxamic acid 
 was achieved in good yield by CDI
mediated activation followed by condensation with NH2OH.HCl, under reported conditions.
36 
Finally, the desired αaminohydroxamic acid  was obtained in the HCl salt form, through NBoc 
deprotection of 
. 
Evaluation of the inhibitory activity of – against PfAM1 and PfAM17 revealed N
Boc protected αaminohydroxamic acid 
 to be a potent, submicromolar inhibitor of both 
enzymes (	). We were therefore curious to investigate the effect that other moieties would 
have at this position. To this end, we developed a series of Nacyl derivatives, based on 
, 
comprising of simple linear and branched alkyl groups as well as substituted aryl moieties. 
Access to these compounds was achieved from the previously synthesized compound  in five to 
six steps (Scheme 2). 
As described above, αketo acid  underwent reductive amination with benzylamine 
rather than N,Ndibenzylamine in order to improve the rate and reaction outcome (the 
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 corresponding reaction with N,Ndibenzylamine proceeded slowly and complete conversion was 
not achieved). The new conditions were successful, and the reaction was complete after 
overnight stirring, generating the Nbenzylamino acid  in good yield.This was subsequently 
esterified with MeOH in the presence of catalytic concentrated H2SO4 (aq), to give the 
corresponding methyl ester . Attempts to obtain through a reversal of the reaction sequence 
(i.e. esterification followed by reductive amination) proved unsuccessful. Heating  under the 
esterification conditions described above resulted in both methyl ester formation as well as 
conversion of the ketone to the corresponding dimethyl ketal. Although selective deprotection of 
the ketal was achieved by standing in TFA,37 attempted reductive amination of the resulting α
keto ester produced several sideproducts by LCMS analysis, including the ketone , the αketo 
alcohol (total reduction of the ester), αhydroxy ester (ketone reduction) and the Nbenzylamino 
acid . 
NDebenzylation of  was achieved as described under acidic hydrogenation conditions 
in excellent yield, affording αamino ester  as the HCl salt. Compound  underwent acylation 
with a selection of alkyl and substitutedbenzoyl chlorides, benzoic acids and tertbutyl 
isocyanate. Where acid chlorides or tertbutyl isocyanate were used as the electrophile, these 
were simply stirred with in the presence of a slight excess of TEA, to give the corresponding 
amides or urea in excellent yield, with only aqueous workup required to isolate the desired 
product cleanly. Coupling to substitutedbenzoic acids was achieved in the presence of 
HCTU/DIPEA in DMF at room temperature, once again with only simple aqueous workup 
necessary to afford high purity amide product. The nitrobenzamides  ! were reduced to the 
corresponding aminobenzamides over 10% Pd/C in MeOH under a hydrogen atmosphere in 
excellent yield. 
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 Evaluation of the literature indicated successful aminolysis of simple esters on similar 
scaffolds with NH2OH.HCl directly.
3844 Such a conversion is attractive, as it removes the need 
to hydrolyse the ester prior to a coupling step. After conducting successful pilot reactions, we 
opted to employ the combination of NH2OH.HCl and methanolic KOH.
43 These conditions gave 
mixed results for the conversion of methyl esters  and  to the corresponding 
hydroxamic acids. Following the literature procedure, we obtained desired compounds in modest 
yield in the majority of cases, with the remainder of reactions affording the corresponding 
carboxylic acid (through basic hydrolysis) as the major product. Even in cases where the desired 
hydroxamic acid was successfully isolated, generation of the carboxylic acid product was also 
noted. Where only the carboxylic product was isolated, this was converted to the corresponding 
hydroxamic acid product using CDImediated activation as described earlier in the synthesis of 

. 
Further optimization of the aminolysis conditions allowed more consistent conversion to 
the desired hydroxamic acid product, with a lower proportion of hydrolysis to the carboxylic acid 
being observed by LCMS analysis. These conditions involved the use of anhydrous MeOH as the 
reaction solvent and to make up the methanolic KOH solution. In addition, the KOH stock 
solution was stored under a septum under an atmosphere of nitrogen to exclude exposure to 
moisture. Finally, rather than sequential addition of NH2OH.HCl and methanolic KOH, the two 
were premixed before addition to the appropriate ester reagent. This was done with a view to 
freshly generate the free NH2OH nucleophile prior to addition, thus reducing the concentration of 
circulating hydroxide ions and reducing the risk of ester hydrolysis. 
"#$%&&#&$'$(#		'$		)*&+$,-./(#-./
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 In synthesizing , the aminohydroxamic acid analogue of aminophosphonic acid , we identified 

, the NBoc precursor of , as a potent inhibitor of both PfAM1 and PfAM17 (	 0
)''		(	). The PfAM1 inhibitory activity of 
 (Ki = 0.8 μM) is approximately 
100 fold higher than that of  (Ki = 104 μM), while the PfAM17 activity is comparable (Ki of  
is 0.011 μM and 
 is 0.03 μM), making 
 the most potent dual PfAM1/M17 inhibitor described 
to date. To assess the selectivity of 
 for PfAM1 and PfAM17 over other MAPs, the inhibitory 
activity against PfM18AAP, another P. falciparum MAP45 was determined. The observed Ki for 
PfM18AAP, 49.6 μM, showed that 
 is > 60fold and 1600fold selective for PfAM1 and PfA
M17 respectively. To investigate the structural mechanism behind the improved PfAM1 and 
PfAM17 potency, we determined the cocrystal structure of compound 
 bound to PfAM1 
(PfAM1:
) and PfAM17 (PfAM17:
). Similarly to ,compound 
 coordinates strongly to the 
catalytic zinc ion/s of both PfAM1 and PfAM17, and probes the hydrophobic S1 pocket with 
the aromatic regions of the compound (namely, a 4(1Hpyrazol1yl)phenyl moiety). However, 
the NBoc group, which is not present on , was observed binding within the S1’ cavity. Since 
the S1’ cavity has not previously been explored with this series of inhibitors, we chose to probe 
the region with a focused library of Nacyl derivatives, assessing dual PfAM1/M17 inhibitory 
activity, and using structural information obtained from a combination of Xray crystallography 
and docking analysis to guide inhibitor development. 
The crystal structures of PfAM1 and PfAM17 bound to selected compounds in the 
series were determined by either cocrystallization or soaking experiments. Similarly to previous 
ligandbound PfAM1 and PfAM17 crystal structures, the only structural differences observed 
on compound binding occurred within proximity of the active sites, while the overall protein 
folds and domain arrangements were unchanged. In all structures, PfAM1 crystallized as a 
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 monomer, with one copy in the asymmetric unit. In accordance with previous observations, PfA
M17 crystallized as a functional hexamer, with two copies in the asymmetric unit; each structure 
of PfAM17 therefore contains a total of twelve binding sites. Although minor differences in 
quality of the ligand electron density is observed between the sites, the compound bindingmode 
is largely conserved. Therefore, for clarity, when referring to structural features, we refer to the 
chain that showed the clearest electron density only (PfAM17:
, chain B; PfAM17:, chain 
C; PfAM17:, chain C). The electron density was such that while racemic mixes of 
compounds were used for crystallization, only the Senantiomer of 
, and the Renantiomer of 
#, , and  could be modeled for both enzymes ()''		(	). 
1	$	$,	231#&	(#(#('$$(
The current series of compounds was anticipated to improve inhibitory potency by 
replacing the phosphonic acid ZBG present on , a potent PfAM1/PfAM17 inhibitor (	
), with a hydroxamic acid moiety. As has been observed for all ligandbound PfAM1 crystal 
structures to date, PfAM1:
 revealed the zinc ion to be coordinated by residues of the catalytic 
triad: His496, His500 and Glu519. In addition, both oxygen atoms of the hydroxamic acid 
moiety also coordinate the zinc ion. The hydroxamic acid moiety takes part in extensive 
hydrogenbonding interactions with active site components: the OH with His500 and Glu497, the 
NH with Glu497 and an ordered water molecule (W1), and the carbonyl with Glu519, Tyr580, 
and W1 (	). In total, the hydroxamic acid forms 12 metallo or hydrogenbonds with 
PfAM1, in comparison to the 7 interactions made by the phosphonic acid of the parent 
compound .  
PfAM17 has two catalytic zinc ions, which are coordinated by Asp459, Lys374, Asp379, 
Asp399 and Glu461. The crystal structure of PfAM17:
 shows the hydroxamic acid moiety 
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 coordinates both catalytic zinc ions, as well as forming hydrogen bonds to five active site 
residues: Leu487, Lys374, Asp379, Asp459 and Lys386. Additionally, the moiety forms a water
mediated hydrogen bond with Asp399, and interacts with the active site carbonate ion present in 
all PfAM17 structures (	 ). Overall the hydroxamic acid of 
 can make fourteen 
potential interactions with PfAM17, whereas the aminophosphonic acid moiety present on  
makes only eight. While the hydroxamic acid of 
 and phosphonic acid of  are bound in 
comparable positions in both PfAM1 and PfAM17, the orientation of the 4(1Hpyrazol1
yl)phenyl system, which is common to both compounds, varies considerably (	&(##). 
In the active sites of both enzymes, the 4(1Hpyrazol1yl)phenyl system of 
 is substantially 
translated and additionally rotated compared to . This places the biaryl system of 
 in a different 
region of the pockets, stacking between Tyr575 and Val459 in PfAM1:
, and Phe398, Met396, 
and Gly489 in PfAM17:
. While few other direct interactions are observed between the 4(1H
pyrazol1yl)phenyl system and enzyme in either the PfAM1:
 or PfAM17:
 structures, the 
binding pose of 
 is more reminiscent of that observed for Bestatin than that of the parent 
aminophosphonic acid . Bestatin is a PheLeu analogue inhibitor based on the transition state of 
the proteolysis reaction performed by PfAM1 and PfAM17. When the Bestatinbound PfAM1 
(3EBH) 7 and PfAM17 (3KR4) 9 structures are overlaid with the corresponding structures bound 
to 
, the benzyl group (Phe sidechain) of Bestatin sits in the same position as the 4(1Hpyrazol
1yl)phenyl moiety, and the NBoc group of 
 occupies the same pocket as the Leu sidechain of 
Bestatin ()''		(	(#). It is the altered binding position of 
 compared to 
that of  that allows the NBoc group access to the S1’ pocket. In PfAM1:and PfAM17:, the 
nitrogen atom of the 2amino group points away from the S1’ pocket and forms hydrogen bonds 
with Glu463 and Glu319 in PfAM1:, and Asp399 in PfAM17:, whereas in PfAM1:
 and 
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 PfAM17:
, the corresponding nitrogen atom (now part of a carbamate group), is positioned to 
allow the NBoc group to access the S1’ pockets ( & (# #). The altered binding pose 
conferred by the scaffold has different effects on PfAM1 and PfAM17 inhibitory activity. The 
aminophosphonic acid  and its structural analogue from the hydroxamic acid series, , have 
similar PfAM1 inhibitory potencies Ki = 104 and 74.5 μM respectively, 	), suggesting 
that the different binding pose does not come at any cost to binding. In contrast, direct exchange 
of the phosphonic acid for the hydroxamic acid ZBG has a detrimental effect on PfAM17 
inhibitory activity;  has a Ki of 0.011 μM compared to 86 μM for .  
The change in binding pose of  versus 
 could result from either the geometry of the 
different ZBG and the nature of its interaction with the zinc ion(s), and/or, steric limitations in 
the PfAM1 and PfAM17 S1 site for accommodation of the N1Boc group. To determine whether 
one or both of these factors promotes the altered binding pose, we docked  into both enzymes 
()''		(	(#). In PfAM1:#$&!, the ligand has a similar binding pose to 
 
(		), with the amine directed towards the S1’ pocket and forming hydrogen bonds with 
the main chain nitrogen and oxygen atoms of Ala461. Thus, in PfAM1 it appears that the 
distinct interaction of the hydroxamic acid ZBG with the zinc ion may be responsible for the 
translated binding pose, relative to that of . The structure of PfAM17:#$&! positions the ligand 
further from the S1’ pocket, towards the S1 pocket (	,). This suggests that the N1Boc 
group present on 
, functions as an S1’anchor, and in its absence there may be some mobility of 
compound binding that contributes to the reduced affinity of this inhibitor. Regardless, similarly 
to PfAM1:dock, the binding pose of  in PfAM17:dock is similar to that observed for 
, again 
suggesting that it is the geometry of the ZBG that dictates the binding pose of 
, not the NBoc 
group. The altered binding pose observed upon substitution of the phosphonic acid for a 
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 hydroxamic acid suggests that exchange of a ZBG late in the lead optimization process may not 
be practical for the retention of other binding interactions in the active site. However, for this 
compound series, the altered binding pose fortuitously offers the opportunity to exploit further 
interaction with the S1’ pocket. 
$'$(#)-4,$	)*'$&!	#,,		(,$-./+	-./

The consequence of the altered binding pose brought about by substitution of the series’ ZBG is 
that further functionalization of the free amine of  offers the potential to exploit binding 
interactions with the S1’ pocket which were previously unavailable to this compound series. In 
both PfAM1:
 and PfAM17:
, the hydrophobic NBoc group sits in the S1’ pocket, in the 
position occupied by the side chain of Leu in Bestatin, forming favorable interactions with 
hydrophobic residues (Val493 in PfAM1; Ala460 and Ile547 in PfAM17) (	(#). 
To probe the steric tolerance of these pockets, compounds with a range of aliphatic N1acyl 
groups (.	) as well as substituted Nbenzoyl groups (,) were tested for inhibitory activity 
at both PfAM1 and PfAM17; their capability to occupy the S1’ pocket examined using a 
combination of crystal and docked structures.  
The Nacetyl derivative  was found to have opposing effects on the inhibition of PfA
M1 and PfAM17. Whilst its PfAM1 inhibitory potency is roughly comparable to  ( Ki = 74.5 
μM,  Ki = 113 μM), it exhibited a considerable improvement in inhibitory potency for PfA
M17 ( Ki = 86 μM,  Ki = 0.019 μM) (	 ). The docked structure of PfAM17:
suggests that the additional carbonyl group is capable of picking up a hydrogen bonding 
interaction with the backbone amine of Gly489 ()''		(	). This interaction is 
also observed in the structure of Bestatin bound to PfAM17, suggesting that it is also common 
to substrates of the enzyme, and therefore a good target in inhibitor design.  
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 As the size and branching of the N1acyl group increases, from acetyl (), to propionyl 
(), to isovaleryl (&), through to pivaloyl (#), a corresponding improvement in PfAM1 
inhibitory potency is observed (Ki = 113 μM, 41.3 μM, 12.3 μM and 0.7 μM respectively, 	
). This indicates that increasing the steric bulk of the Nacyl substituent is favorable for binding 
to the PfAM1 S1’ pocket. Docking analysis of each of these compounds indicates that their 
binding modes are highly conserved ()''		(	), suggesting that the additional 
space occupied by the larger substituents within the hydrophobic pocket contributes to improved 
binding. Compound # and 
, the most potent PfAM1 inhibitors of the series, both bear tert
butyl moieties; however # bears an amide linker, compared to the corresponding carbamate 
linker present on 
. The tert1butyl moiety of # is therefore relatively closer to the ZBG. In the 
structure of PfAM1:
, the tertbutyl group sits deep within the S1’ pocket and forms 
hydrophobic contacts with Val493 at the base. It was therefore not surprising that in the structure 
of PfAM1:#dock the shorter substituent of # does not occupy the same space as the 
equivalent group in 
, and is unable to form hydrophobic interactions with Val493. However, 
given the lack of any additional interactions capable of compensating for this loss, it was curious 
thatboth 
 and # demonstrated equivalent inhibitory potencies (Ki values of 0.8 μM and 0.7 
μM respectively). We therefore determined the cocrystal structure of PfAM1 in complex with 
# (PfAM1:#). While a racemic mixture of the ligand was used for crystallization, only the 
Renantiomer of # was observed to bind PfAM1. This observation is in contrast to the PfA
M1:
 structure, which showed only the Senantiomer bound (	 ). The switch in 
enantiomeric preference allows the tertbutyl group of # to occupy a similar space to that of 
, 
and to maintain the hydrophobic interactions with Val493. This adjustment to maintain the 
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 interaction with Val493 emphasizes the importance of the interaction in the S1’ pocket of PfA
M1.  
Catalytically, PfAM17 has a clear preference for bulky hydrophobic residues,46 therefore 
it was anticipated that compounds bearing increasingly hydrophobic Nacyl moieties would 
exhibit improved inhibitory potency. However, in contrast to the SAR observed with PfAM1, an 
increase in hydrophobic steric bulk from  through to # showed very little effect on 
inhibition of PfAM17 (	). When docked into the active site ()''		(	), 
it was observed that these compounds all form a hydrogen bond with Gly489 through the amide 
carbonyl oxygen atom. This hydrogen bond orientates short alkyl substituents out of the main 
hydrophobic S1’ cavity (	 ), explaining why additional steric presence in this region 
does not contribute to binding affinity.  
The tolerance of the PfAM1 S1’ pocket to a variety of substituted aromatic moieties was 
then examined with N1benzoyl (,) and N1(fluoro)benzoylsubstituted derivatives (.). 
Docking analysis showed that the phenyl group of , cannot be accommodated within 
interaction distance to Val493, and is instead directed to solvent, accounting for the reduced PfA
M1 inhibitory potency. Although the N1(fluorobenzoyl)substituted compounds regained some of 
this potency, none inhibited PfAM1 as well as 
 or #. However, beyond the hydrophobic edge 
of the S1’ pocket of PfAM1, the region becomes increasingly solvated within the large C
terminal channel. This is the putative substrate entry channel, where both hydrophilic residues 
and ordered water molecules are observed. To take advantage of this dual nature of the pocket, 
N1(amino)benzoyl substituted derivatives  and  were also examined. Both compounds 
demonstrated moderate inhibitory activity (5.5 μM and 7.4 μM respectively, 	 ), and 
comparison of the crystal structure of PfAM1: and the docked structure of PfAM1:#$&!, 
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 showed that the aminosubstituent is placed in a similar position for both binding poses, where it 
is able to form a direct hydrogen bond with Arg489, in addition to watermediated hydrogen 
bonds with Glu526 (	 &). Elaboration of this moiety to take advantage of additional 
hydrogen bonding partners may lead to an improved PfAM1 inhibitory potency of these 
compounds. 
The same series of substituted N1benzoyl compounds (.,and.), was tested for 
PfAM17 inhibitory activity, and was found to effectively recover the loss of potency exhibited 
by ,. To determine the structural rationale for this difference, both  and  were co
crystallized with the enzyme. The two compounds bound with nearidentical binding poses, with 
only the Renantiomers of each observed. Similarly to .# at PfAM1, these enantiomers 
allows the N1acylsubstituent to probe deeper into the S1’ pocket. This region of the pocket 
contains more hydrophilic residues than the neck of the pocket, making it more favorable for the 
electronegative fluoro or polar amino substituents to occupy (	#). However, no direct 
interactions with the pocket were observed, and little variation was observed in compound 
inhibitory potencies. There does appear to be additional space in the PfAM17 S1’ pocket, 
specifically a small auxiliary cavity, that is not occupied by . (	#); further extension 
of this region of the scaffold to better fit the pocket may offer improvements in PfAM17 
inhibition. Conversely, such extension is likely to be detrimental to PfAM1 inhibitor potency, as 
the PfAM1 S1’ pocket is less tolerant to aromatic moieties in this region.  
"#$%&&#&$'$(#		(	$5$,	
6

The described series of hydroxamic acidbased compounds contain the most potent dual 
PfAM1/PfAM17 inhibitors described to date. We therefore determined the ability of these 
compounds to inhibit the growth of the asexual erythrocytic stages of Pf3D7 parasites, utilizing 
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 a wellestablished Pf imaging assay ()''		(	).47 Briefly, parasite number (and 
thus growth inhibition) was determined through measurement of the incorporation of the DNA
intercalating dye 4',6diamidino2phenylindole into the parasite nucleus following exposure to 
compounds. Fluorescent images acquired on the PerkinElmer’s Opera® were analyzed with a 
spot detection algorithm using the Acapella® software. Previous potent PfAM1/PfAM17 
inhibitors Bestatin and CHR6768 have been reported to demonstrate inhibitory potencies 
between 0.4 – 5 μM for Pf3D7 parasite growth. Compounds from our present series inhibit 
parasite growth with IC50 values between 0.2 – 0.7 μM (	), with the variation in potency 
in general agreement with changes in PfAM1/PfAM17 inhibitory activity. Compound #, the 
most effective PfAM1 inhibitor (Ki = 0.7 μM) and one of the more potent PfM17 inhibitors (Ki 
= 0.028 μM), is the most effective compound against 3D7 malaria parasites, with an IC50 of 227 
nM (	). Although the in vitro inhibitory properties of compound 
 are comparable to #, 
it has an IC50 for parasite growth of only 783 nM, suggesting that compounds substituted with 
the NBoc group are either less capable of cellular penetration, or less stable than the 
corresponding Nacyl derivatives. Compounds  and  are also highly effective against the 
malaria parasites (IC50 values of 233 and 228 nM respectively), despite slightly reduced affinity 
for PfM1 compared to # (and comparable activity for PfM17). This could be attributed to 
indirect factors, such as improved cellular penetration, or protozoan cytotoxicity arising from 
toxic metabolites produced by the parasite, which has the potential to be metabolically active 
during the 3D7 assay.  We additionally screened all of the compounds in the series for 
cytotoxicity against human embryonic kidney cells (HEK293), and saw no observable 
cytotoxicity at concentrations up to 40 μM ()''		(	). Although we are yet to 
perform stability and distribution studies, previous analyses of hydroxamic acid based inhibitors 
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 suggest that the scaffold is capable of reaching the site of action within cultured erythrocytes,10 
making this a promising scaffold for further development. 
Hydroxamatecontaining inhibitors of human Aminopeptidase N have been identified,48 
and Bestatin has undergone clinical trials as an immunomodulating agent.49, 50 Therefore, the 
potential for the compounds described here to act upon the human isoforms of PfAM1 and / or 
PfAM17 in vitro cannot be discounted. However, the lack of any observed toxicity of our 
compounds in HEK293 cells is encouraging for the continued development of the series. 
Homologous M1 and M17 aminopeptidases also function as key enzymes in other parasites51, 52 
and bacterial pathogens.53, 54 This compound series may therefore have potential applications for 
the development of other MAP inhibitors for the treatment of a range of diseases. 
 
CONCLUSIONS 
The Pf aminopeptidases M1 and M17 are validated drug targets for antimalarial agents with a 
novel mode of action. While previous inhibitor series’ demonstrated that crossinhibition was 
possible, differences in the compound binding profiles of the enzymes meant that compound 
elaboration tended towards improved inhibition of one enzyme target at the expense of the other. 
We report here the first series of compounds capable of potent dual inhibition of both PfAM1 
and PfAM17. The series additionally possesses activity against 3D7 malaria parasites and no 
observable cytotoxicity. This hydroxamic acid based series of compounds therefore provides 
extremely attractive lead molecules for further development into antimalarial compounds with a 
novel mode of action. 
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 EXPERIMENTAL SECTION 
	 Chemicals and solvents were purchased from standard suppliers and used without 
further purification.  Davisil® silica gel (4063 µm), for flash column chromatography (FCC) 
was supplied by Grace Davison Discovery Sciences (Victoria, Australia) and deuterated solvents 
were purchased from Cambridge Isotope Laboratories, Inc. (USA, distributed by Novachem 
PTY. Ltd, Victoria, Australia).
Unless otherwise stated, reactions were carried out at ambient temperature. Reactions 
were monitored by thin layer chromatography on commercially available precoated aluminium
backed plates (Merck Kieselgel 60 F254). Visualisation was by examination under UV light (254 
and 366 nm).  General staining carried out with KMnO4 or phosphomolybdic acid. A solution of 
Ninhydrin (in ethanol) was used to visualize primary and secondary amines. A solution of 
Fe(III)Cl3 (5% in 0.5 M HCl(aq)) was used to visualise hydroxamic acids. All organic extracts 
collected after aqueous workup procedures were dried over anhydrous Na2SO4 before gravity 
filtering and evaporation to dryness.  Organic solvents were evaporated in vacuo at ≤ 40°C 
(water bath temperature).  Purification using preparative layer chromatography (PLC) was 
carried out on Analtech preparative TLC plates (200 mm x 200 mm x 2 mm). 
1H NMR and 13C NMR spectra were recorded on a Bruker Avance Nanobay III 400 MHz 
Ultrashield Plus spectrometer at 400.13 MHz and 100.6 MHz respectively. Chemical shifts (δ) 
are recorded in parts per million (ppm) with reference to the chemical shift of the deuterated 
solvent.  Coupling constants (J) and carbonfluorine coupling constants (JCF) are recorded in Hz 
and the significant multiplicities described by singlet (s), doublet (d), triplet (t), quadruplet (q), 
broad (br), multiplet (m), doublet of doublets (dd), doublet of triplets (dt).  Spectra were assigned 
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 using appropriate COSY, distortionless enhanced polarisation transfer (DEPT), HSQC and 
HMBC sequences. 
LCMS were run to verify reaction outcome and purity using either system A or B. 
)	-7 an Agilent 6100 Series Single Quad coupled to an Agilent 1200 Series HPLC. The 
following buffers were used; buffer A: 0.1% formic acid in H2O; buffer B: 0.1% formic acid in 
MeCN.  The following gradient was used with a Phenomenex Luna 3µM C8(2) 15 x 4.6 mm 
column, and a flow rate of 0.5 mL/min and total run time of 12 min; 0–4 min 95% buffer A and 
5% buffer B, 4–7 min 0% buffer A and 100% buffer B, 7–12 min 95% buffer A and 5% buffer 
B.  Mass spectra were acquired in positive and negative ion mode with a scan range of 0–1000 
m/z at 5V. UV detection was carried out at 254 nm. )	37 an Agilent 6120 Series Single 
Quad coupled to an Agilent 1260 Series HPLC. The following buffers were used; buffer A: 0.1% 
formic acid in H2O; buffer B: 0.1% formic acid in MeCN.  The following gradient was used with 
a Poroshell 120 ECC18 50 x 3.0 mm 2.7 micron column, and a flow rate of 0.5 mL/min and 
total run time of 5 min; 0–1 min 95% buffer A and 5% buffer B, from 12.5 min up to 0% buffer 
A and 100% buffer B, held at this composition until 3.8 min, 3.8–4 min 95% buffer A and 5% 
buffer B, held until 5 min at this composition.  Mass spectra were acquired in positive and 
negative ion mode with a scan range of 100–1000 m/z. UV detection was carried out at 214 and 
254 nm. All retention times (tR) are quoted in minutes. 
Preparative HPLC was performed using an Agilent 1260 infinity coupled with a binary 
preparative pump and Agilent 1260 FCPS fraction collector, using Agilent OpenLAB CDS 
software (Rev C.01.04), and an Altima 5 µM C8 22 x 250 mm column. The following buffers 
were used; buffer A: H2O; buffer B: MeCN, with sample being run at a gradient of 5% buffer B 
Page 20 of 65
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 to 100% buffer B over 20 min, at a flow rate of 20 mL/min All screening compounds were of > 
95% purity unless specified in the individual monologue.
1	(	 8$&	#	 -7 $(#	($( $, 	 ..".'9$..'	(..
($&		 #$&$#	  5 &# &$#	 (# $&(	  Methyl 2(4(1H
pyrazol1yl)phenyl)2aminoacetate hydrochloride  (134 mg, 0.50 mmol) and TEA (0.154 
mL, 1.10 mmol, 2.2 eq in the case of acid chlorides or 0.077 mL, 0.55 mmol, 1.1 eq in the case 
of isocyanates) were dissolved in DCM (3 mL). To this was added the appropriate acid chloride 
(0.55 mmol, 1.1 eq), and the mixture stirred at room temperature for 18 h. Reaction progress was 
monitored by TLC (EtOAc/DCM 1:1). On completion, the reaction mixtures were diluted with 
DCM (10 mL) and washed with water (10 mL). Concentration of the organic layer afforded the 
product, which was carried through to the next step with no further purification necessary. 
1	(	 8$&	#	 37 6	& ($ $, 	 		 $ &$	'$(#(
#$%& &#  	:	( ##$( $, 		(  The appropriate methyl ester (0.40–
0.55 mmol) and NH2OH.HCl (139 mg, 2 mmol) were dispersed in MeOH (2 mL) at room 
temperature. To this was added in a dropwise fashion, 5M KOH/MeOH (0.5 mL, 2.5 mmol) 
further diluted in MeOH (to 10 mL). The mixtures were stirred at room temperature and 
monitored by LCMS analysis. The mixtures were concentrated before acidification with either 
1M HCl (aq) (10 mL) or AcOH/water (1:1, 10 mL, for more acid sensitive compounds). The 
aqueous slurry was then extracted with EtOAc (3 x 10 mL), and the combined organic layers 
washed with brine (10 mL), then dried of Na2SO4. Concentration of the organic layers gave the 
crude product, which was further purified by FCC (eluent MeOH/DCM 0:100 to 10:90). 
1	(	 8$&	#	 7 6	& ($ $, 	 		 $ &$	'$(#(
#$%& &# 5 '	%( $, 		( ( (#$ /	;"  The appropriate 
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 methyl ester (0.40–0.55 mmol) was dissolved in anhydrous MeOH (0.5 mL) at room temperature 
in a nitrogen flushed vessel. In a separate nitrogen flushed vial, NH2OH.HCl (139 mg, 2 mmol) 
and 5M KOH/anhydrous MeOH (0.5 mL, 2.5 mmol) were mixed, then sonicated for 30 sec. The 
resulting suspension was added to the methanolic ester solution with washings of anhydrous 
MeOH (1 mL). The mixtures were stirred at room temperature overnight and monitored by 
LCMS analysis. The mixtures were directly dryloaded on to Isolute HMN® (Biotage), before 
purification by FCC (eluent MeOH/DCM 0:100 to 10:90). 
1	(	8$&	#	676<.	#	#&$'($,&$%&&#$#$%(	
$ +	 	 &$	'$(#( #$%& &#  The appropriate carboxylic acid (1 eq) was 
dissolved in anhydrous THF (15 mL/mmol) at room temperature under an atmosphere of 
nitrogen, and CDI (1.5 eq) was added. The mixture was stirred at room temperature for 1 h, 
before adding in NH2OH.HCl (2 eq). Stirring was continued at room temperature for 24 to 48 h, 
before diluting the mixture with sat. NH4Cl (aq) (20 mL), then extracting with EtOAc (3 x 20 
mL). The combined organic layers were washed with sat. NaHCO3 (aq) (20 mL) and brine (20 
mL), before concentration under reduced pressure. The resulting crude product was further 
purified by FCC (eluent MeOH/DCM 0:100 to 10:90). 
...89$..'	(	(..$(	 
31 4’Iodoacetophenone () (16.15 g, 
65.63 mmol), pyrazole (4.92 g, 72.19 mmol, 1.1 eq) and Cs2CO3 (42.77 g, 131.26 mmol, 2.0 eq) 
were placed in a dry flask under an atmosphere of nitrogen. To this was added dry DMF (100 
mL). The solution was degassed by sonication before adding Cu2O (939 mg, 6.56 mmol, 0.1 eq) 
and heating at 100°C for 17.5 h. The mixture was cooled, before diluting with water (400 mL), 
then extracting with EtOAc (4 x 100 mL). The combined organic layers were washed with brine 
(100 mL), before drying over MgSO4, then passing the organic solution through a plug of silica 
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 gel. The filtrate was concentrated under reduced pressure, and the resulting residue dissolved in 
DCM and passed through a second plug of silica gel, initially washing with DCM, followed by 
elution with EtOAc/DCM (1:1). On concentration of the filtrate 11.8 g of pale blue solid was 
obtained (97%). 1H NMR (CDCl3) δ 8.10 – 8.04 (m, 2H), 8.01 (d, J = 2.5 Hz, 1H), 7.85 – 7.79 
(m, 2H), 7.77 (d, J = 1.5 Hz, 1H), 6.52 (dd, J = 2.4/1.9 Hz, 1H), 2.62 (s, 3H); 13C NMR (CDCl3) 
δ 197.0, 143.4, 142.2, 135.0, 130.1, 127.1, 118.5, 108.7, 26.7; m/z MS (TOF ES+) C11H11N2O 
[MH]+ calcd 187.1; found 187.2; LCMS tR: 3.50. 
...89$..'	(..$%$&	& &#  1(4(1HPyrazol1
yl)phenyl)ethan1one  (11.8 g, 63.37 mmol) and SeO2 (9.6 g, 86.52 mmol, 1.37 eq) were 
dispersed in anhydrous pyridine (300 mL) under an atmosphere of nitrogen gas, and heated 
under reflux at 110°C for 20 h. LCMS analysis indicated almost complete conversion to the 
desired product, so SeO2 (3.516 g, 31.69 mmol, 0.5 eq) was added before continuing heating for 
a further 5 h. LCMS analysis indicated the reaction was complete so the reaction was cooled to 
room temperature with stirring overnight. The mixture was filtered, and the filtrate concentrated 
under reduced pressure to remove pyridine. The resulting residue was taken up in 2M HCl(aq) 
(200 mL) and extracted with EtOAc (300 mL, 2 x 200 mL, 100 mL). The combined organic 
layers were then extracted with 2M NaOH(aq) (2 x 100 mL). The combined aqueous extracts were 
reacidified with conc. HCl(aq) and reextracted with EtOAc (3 x 200 mL). Finally the combined 
organic layers were washed with brine (100 mL). The combined organic layers were 
concentrated until precipitation was observed. At this point, excess hexanes were added to the 
flask and the resultant precipitate collected by filtration (vacuum). After drying, 12.58 g (92%) 
of pale yellow solid were obtained. 1H NMR (DMSO) δ 14.75 (s, 1H), 8.77 – 8.65 (m, 1H), 8.17 
– 8.02 (m, 4H), 7.87 (d, J = 1.5 Hz, 1H), 6.65 (dd, J = 2.6/1.7 Hz, 1H); 13C NMR (DMSO) δ 
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 184.3, 163.0, 141.1, 139.6, 128.5, 126.2, 125.7, 115.3, 106.2; m/z MS (TOF ES+) C11H9N2O3 
[MH]+ calcd 217.1; found 217.1; LCMS tR: 2.67. 
...89$..'	(..
.$%&$(($&	& &#  2(4
(1HPyrazol1yl)phenyl)2oxoacetic acid  (500 mg, 2.31 mmol) was dispersed in dry 1,2
dichloroethane (20 mL) under an atmosphere of nitrogen. To this was added N,Ndibenzylamine 
(913 mg, 0.890 mL, 4.63 mmol, 2 eq). The mixture was stirred at room temperature for 5 min, 
before addition of Na(OAc)3BH (980 mg, 4.63 mmol, 2 eq). The mixture was then stirred at 
room temperature overnight. Workup of a small sample of reaction mixture in water/EtOAc and 
LCMS analysis of each layer showed starting material and N,Ndibenzylamine partitioned into 
the aqueous layer, whereas the EtOAc layer contained product and some N,Ndibenzylamine. 
Further Na(OAc)3BH (490 mg, 2.31 mmol, 1 eq) was added and stirring continued at room 
temperature overnight. The mixture was diluted with water (50 mL), and stirred for 5 min, before 
extraction with EtOAc (3 x 50 mL). The combined organic layers were then washed with brine 
(50 mL), with the brine washings kept separate from the initial water layer. On washing with 
brine, precipitation of a white solid occurred. This was collected by filtration (vacuum) of both 
organic and brine layers, and washing the collected solid with water. LCMS analysis of this salt 
indicated it was the acetate salt of N,N1dibenzylamine. The organic layers were concentrated 
under reduced pressure, and further purified by FCC (eluent MeOH/DCM 0:100 to 5:95), to give 
89 mg of N(4(1Hpyrazol1yl)benzyl)Nbenzyl1phenylmethanamine (decarboxylated 
product) and 702 mg of desired product contaminated with N,N1dibenzylamine. 
The crude desired product was dissolved in MeOH/water (9:1, 20 mL), before adding 
10% Pd/C (70 mg). The mixture was hydrogenated (balloon) at room temperature overnight. 
LCMS analysis indicated almost complete monodebenzylation, so water (15 mL) and conc. 
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 HCl(aq) (1 mL) were added, along with further 10% Pd/C (70  mg), before continued 
hydrogenation at room temperature for 3.5 h. LCMS analysis after this time indicated complete 
Nbenzyl deprotection to the primary amine had occurred. The mixture was filtered through a 
bed of Celite (vacuum), with washings of MeOH, before concentration under reduced pressure. 
The resulting crude residue was taken up in water (20 mL) and washed with Et2O (20 mL), 
before basifying with sat. NaHCO3 (aq). The aqueous layer was washed again with Et2O (20 mL) 
and the organic layer discarded. Boc2O (555 mg, 2.54 mmol) was added to the aqueous layer, 
and the mixture stirred at room temperature for 30 min, before addition of further Boc2O (252 
mg, 1.15 mmol) and THF (10 mL). The mixture was allowed to stir at room temperature 
overnight. After this time the mixture was carefully acidified to pH 4 with 2M HCl(aq), before 
extraction with DCM (3 x 50 mL). The combined organic layers were concentrated under 
reduced pressure, before further purification be FCC (eluent MeOH/DCM 0:100 to 10:90) to 
give 410 mg of foamy white solid (56% over 3 steps). 1H NMR (DMSO) δ 12.86 (s, 1H), 8.49 
(d, J = 2.4 Hz, 1H), 7.81 (d, J = 8.5 Hz, 2H), 7.74 (d, J = 1.5 Hz, 1H), 7.66 (d, J = 8.3 Hz, 1H), 
7.51 (d, J = 8.6 Hz, 2H), 6.54 (dd, J = 2.3/1.9 Hz, 1H), 5.15 (d, J = 8.2 Hz, 1H), 1.39 (s, 9H); 13C 
NMR (DMSO) δ 172.2, 155.2, 141.1, 139.2, 135.3, 128.9, 127.8, 118.3, 107.9, 78.5, 57.1, 28.2; 
m/z MS (TOF ES+) C16H20N3O4 [MH]
+ calcd 318.1; found 318.2; LCMS tR: 3.18. 
...89$..'	(..($&	& &# #$&$#	  2(4(1H
Pyrazol1yl)phenyl)2((tertbutoxycarbonyl)amino)acetic acid ( (38 mg, 0.12 mmol) was 
dissolved in DCM (3 mL), before adding 4M HCl/1,4dioxane (1 mL). The mixture was stirred 
at room temperature for 1 h, before concentrating under reduced pressure to give 29 mg of white 
solid (97%). 1H NMR (DMSO) δ 13.96 (s, 1H), 8.91 (s, 3H), 8.55 (d, J = 2.4 Hz, 1H), 7.94 (d, J 
= 8.7 Hz, 2H), 7.78 (d, J = 1.5 Hz, 1H), 7.63 (d, J = 8.7 Hz, 2H), 6.58 (dd, J = 2.4/1.8 Hz, 1H), 
Page 25 of 65
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 5.18 (s, 1H); 13C NMR (DMSO) δ 169.7, 141.4, 140.2, 130.9, 129.5, 128.0, 118.6, 108.3, 54.9; 
m/z MS (TOF ES+) C11H12N3O2 [MH]
+ calcd 218.1; found 218.1; LCMS tR: 1.39. 

.3 ...'9$..'	(..#$%($..$%$	&	

 Pyrazol1yl)phenyl)2((tertbutoxycarbonyl)amino)acetic acid ( (100 mg, 0.32 mmol) 
was dissolved in dry THF (1 mL) under an atmosphere of nitrogen at room temperature. To this 
was added CDI (76 mg, 0.47 mmol, 1.5 eq), and the mixture stirred for 1 h at room temperature. 
Hydroxylamine hydrochloride (44 mg, 0.63 mmol, 2 eq) was added and the mixture was then 
stirred at room temperature overnight. LCMS analysis indicated approximately 75% conversion 
had taken place, so stirring was continued for a further 3 days. Sat. NH4Cl(aq) (20 mL) was added, 
before extracting with EtOAc (3 x 20 mL). The combined organic layers were then washed with 
brine (20 mL). After concentration of the organic layers, the crude residue was further purified 
by PLC (NH4OH/MeOH/DCM 1:10:89), with the plate being run twice, to give 73 mg of white 
solid (69%). 1H NMR (DMSO) δ 10.91 (s, 1H), 9.00 (s, 1H), 8.48 (d, J = 2.4 Hz, 1H), 7.79 (d, J 
= 8.7 Hz, 2H), 7.73 (d, J = 1.4 Hz, 1H), 7.58 – 7.45 (m, 3H), 6.54 (dd, J = 2.4/1.8 Hz, 1H), 5.08 
(d, J = 8.6 Hz, 1H), 1.38 (s, 9H); 13C NMR (DMSO) δ 171.7, 166.9, 141.0, 139.1, 134.2, 128.3, 
127.8, 118.2, 107.9, 80.5, 54.9, 28.2; m/z MS (TOF ES) C16H19N4O4 [MH]
 calcd 331.1; found 
331.2; LCMS tR: 3.02. 
...89$..'	(..($..#$%&	#	#$&$#	 tert
Butyl (1(4(1Hpyrazol1yl)phenyl)2(hydroxyamino)2oxoethyl)carbamate(
) (62 mg, 0.19 
mmol) was dissolved in MeOH/DCM (1:1, 4 mL). To this was added 4M HCl/1,4dioxane (2 
mL) and the mixture stirred at room temperature for 2 h. The mixture was concentrated under 
reduced pressure, to give 47 mg of hygroscopic yellow solid. This was further purified by 
preparative HPLC to give 13 mg of colourless semisolid (25%). 1H NMR (MeOD) δ 8.29 (d, J = 
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 2.5 Hz, 1H), 7.87 (d, J = 8.6 Hz, 2H), 7.75 (d, J = 1.5 Hz, 1H), 7.64 (d, J = 8.6 Hz, 2H), 6.56 (dd, 
J = 2.4/1.9 Hz, 1H), 4.86 (s, 1H); 13C NMR (MeOD) δ 167.0, 142.7, 142.3, 133.5, 130.3, 129.1, 
120.7, 109.3, 55.6; m/z MS (TOF ES+) C11H13N4O2 [MH]
+ calcd 233.1; found 233.1; LCMS tR: 
1.49. 
...89$..'	(..	(9($&	& &#  2(4(1HPyrazol1
yl)phenyl)2oxoacetic acid  (6.00 g, 27.75 mmol) was dispersed in anhydrous 1,2
dichloroethane (240 mL) under an atmosphere of nitrogen at room temperature. To this stirred 
suspension, was added benzylamine (5.95 g, 6.06 mL, 55.51 mmol, 2 eq), and stirring continued 
at room temperature for 5 min. Na(OAc)3BH (11.77 g, 55.51 mmol, 2 eq) was added in portions, 
and stirring was continued at room temperature overnight. The mixture was concentrated, and 
the resulting residue partitioned between water (200 mL) and EtOAc (100 mL), and stirred for 30 
min at room temperature. The organic solvent was then removed under reduced pressure, and the 
resulting solid collected by filtration (vacuum) and washed with water. After drying, 6.45 g 
(76%) of offwhite solid was obtained, which was used without further purification. 1HNMR 
analysis proved difficult due to poor solubility in a variety of solvents, including DMSO, 
obtained spectra were difficult to interpret due to peak broadness. LCMS analysis gave a single 
peak with the correct mass, so NMR analysis was carried out in the subsequent step to confirm 
structure. m/z MS (TOF ES+) C18H18N3O2 [MH]
+ calcd 308.1; found 308.2; LCMS tR: 3.13. 
/	...'9$..'	(..	(9($&		2(4(1HPyrazol
1yl)phenyl)2(benzylamino)acetic acid (6.34 g, 20.61 mmol) was dispersed in MeOH (200 
mL). To this was added concd H2SO4 (aq) (2 mL), and was boiled under reflux for 24 h, before 
adding in further conc. H2SO4 (aq) (1 mL). Heating was continued for a further 24 h period. 
LCMS analysis indicated the reaction was progressing slowly, so MeOH (100 mL) was added 
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 and heating continued for a further 72 h. LCMS analysis indicated the reaction was complete, so 
the mixture was cooled, before concentrating under reduced pressure. The resulting residue was 
basified with sat. NaHCO3 (aq) (250 mL), before extraction with DCM (3 x 100 mL). The 
combined organic layers were concentrated under reduced pressure, and the resulting residue 
purified by FCC (eluent EtOAc/PE 0:100 to 30:70, with a plateau at 15:85) to give 5.90 g (89%) 
of pale yellow oil. 1H NMR (CDCl3) δ 7.96 – 7.90 (m, 1H), 7.90 – 7.70 (m, 3H), 7.69 – 7.53 (m, 
2H), 7.49 – 7.28 (m, 5H), 6.54 – 6.40 (m, 1H), 4.70 – 4.45 (m, 1H), 4.44 – 4.02 (m, 1H), 3.95 – 
3.75 (m, 2H), 3.75 – 3.64 (m, 2H); 13C NMR (CDCl3) δ 172.2, 141.7, 140.0, 139.9, 138.1, 130.1, 
129.53, 129.4, 129.0, 128.5, 126.9, 119.7, 108.2, 63.6, 53.2, 52.7; m/z MS (TOF ES+) 
C19H20N3O2 [MH]
+ calcd 322.2; found 322.2; LCMS tR: 3.21. 
1H/13C NMR spectra indicate 
multiple conformational states. 
/	...'9$..'	(..($&		#$&$#	 Methyl 2
(4(1Hpyrazol1yl)phenyl)2(benzylamino)acetate  (6.047 g, 18.82 mmol) was dissolved 
in MeOH (250 mL) and conc. (32%) HCl (aq) (4 mL), before adding 10% Pd/C (600 mg, 0.1 eq 
by weight). The mixture was hydrogenated (balloon) at room temperature for 48 h. LCMS 
analysis indicated complete conversion had taken place. The mixture was filtered through a bed 
of Celite, with washings of MeOH. The filtrate was concentrated under reduced pressure, and the 
resulting residue dispersed in sat. NaHCO3 (aq), before extracting with DCM (3 x 100 mL). The 
combined organic layers were concentrated under reduced pressure to give 5.507 g of crude 
product. This was taken up in Et2O/DCM, before adding a solution of 1M HCl/Et2O (25 mL). 
This was stirred at room temperature for 30 min, before diluting with Et2O and filtering the 
resulting precipitate, to give 4.407 g (87%) white amorphous solid. 1H NMR (DMSO) δ 9.13 (d, 
J = 3.3 Hz, 3H), 8.56 (d, J = 2.3 Hz, 1H), 7.94 (d, J = 8.7 Hz, 2H), 7.78 (d, J = 1.5 Hz, 1H), 7.63 
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 (d, J = 8.7 Hz, 2H), 6.58 (dd, J = 2.4/1.8 Hz, 1H), 5.36 (q, J = 5.0 Hz, 1H), 3.73 (s, 3H); 13C 
NMR (DMSO) δ 168.8, 141.5, 140.4, 130.1, 129.7, 128.0, 118.6, 108.3, 54.7, 53.3; m/z MS 
(TOF ES+) C12H14N3O2 [MH]
+ calcd 232.1; found 232.2; LCMS tR: 3.02.
/	 ...'9$..'	(..&	#$&		  Acetyl chloride 
(0.039 mL, 0.55 mmol, 1.1 eq) was reacted as described in General Procedure A. After 24 h, 
further acetyl chloride (0.4 eq) and triethylamine (0.5 eq) were added and stirring continued for 
24 h prior to workup, to give 128 mg (93%) of offwhite solid. 1H NMR (CDCl3) δ 7.91 (d, J = 
2.4 Hz, 1H), 7.73 (d, J = 1.5 Hz, 1H), 7.72 – 7.65 (m, 2H), 7.51 – 7.41 (m, 2H), 6.57 (d, J = 6.7 
Hz, 1H), 6.48 (dd, J = 2.4, 1.9 Hz, 1H), 5.62 (d, J = 7.1 Hz, 1H), 3.75 (s, 3H), 2.31 (s, 1H), 2.06 
(s, 3H); 13C NMR (CDCl3) δ 171.4, 169.5, 141.4, 140.3, 135.0, 128.6, 127.0, 119.8, 108.0, 56.0, 
53.1, 23.2; m/z MS (TOF ES+) C14H16N3O3 [MH]
+ calcd 274.1; found 274.1; LCMS tR: 3.30.
/	 ...'9$..'	(..'$'$(#$&		  Propionyl 
chloride (0.048 mL, 0.55 mmol, 1.1 eq) was reacted as described in General Procedure A, to give 
135 mg (93%) of pale pink solid. 1H NMR (CDCl3) δ 7.95 – 7.89 (m, 1H), 7.75 (d, J = 1.5 Hz, 
1H), 7.73 – 7.66 (m, 2H), 7.50 – 7.42 (m, 2H), 6.52 (d, J = 6.7 Hz, 1H), 6.48 (dd, J = 2.4, 1.9 Hz, 
1H), 5.62 (d, J = 7.0 Hz, 1H), 3.75 (s, 3H), 2.30 (dd, J = 7.6/3.1 Hz, 2H), 2.23 (s, 1H), 1.17 (t, J 
= 7.6 Hz, 3H); 13C NMR (CDCl3) δ 173.2, 171.5, 141.3, 140.2, 135.2, 128.6, 127.1, 119.8, 108.0, 
55.9, 53.1, 29.5, 9.6; m/z MS (TOF ES+) C15H18N3O3 [MH]
+ calcd 288.1; found 288.2; LCMS 
tR: 3.40.
/	 ...'9$..'	(..$#$&		 & Isobutyryl 
chloride (0.058 mL, 0.55 mmol, 1.1 eq) was reacted as described in General Procedure A, to give 
129 mg (85%) of offwhite solid. 1H NMR (CDCl3) δ 7.95 – 7.90 (m, 1H), 7.74 (d, J = 1.7 Hz, 
1H), 7.73 – 7.66 (m, 2H), 7.50 – 7.41 (m, 2H), 6.54 (d, J = 6.7 Hz, 1H), 6.48 (dd, J = 2.4/1.9 Hz, 
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 1H), 5.60 (d, J = 6.9 Hz, 1H), 3.75 (s, 3H), 2.46 (hept, J = 6.9 Hz, 1H), 2.33 (s, 1H), 1.19 (d, J = 
6.8 Hz, 3H), 1.15 (d, J = 6.9 Hz, 3H); 13C NMR (CDCl3) δ 176.4, 171.5, 141.4, 140.2, 135.2, 
128.5, 127.0, 119.8, 108.0, 55.8, 53.1, 35.5, 31.1, 19.6, 19.5; m/z MS (TOF ES+)  C16H20N3O3 
[MH]+ calcd 302.1; found 302.2; LCMS tR: 3.49.
/	 ...'9$..'	(..'+#$&		 # Pivaloyl chloride 
(0.068 mL, 0.55 mmol, 1.1 eq) was reacted as described in General Procedure A, to give 152 mg 
(96%) of offwhite solid. 1H NMR (CDCl3) δ 7.92 (d, J = 2.4 Hz, 1H), 7.76 (d, J = 1.6 Hz, 1H), 
7.70 (d, J = 8.6 Hz, 2H), 7.45 (d, J = 8.5 Hz, 2H), 6.72 (d, J = 6.3 Hz, 1H), 6.56 – 6.40 (m, 1H), 
5.56 (d, J = 6.6 Hz, 1H), 3.75 (s, 3H), 2.24 (s, 1H), 1.23 (s, 9H); 13C NMR (CDCl3) δ 178.0, 
171.6, 141.3, 140.2, 135.3, 128.5, 127.0, 119.9, 108.0, 56.0, 53.1, 38.8, 27.5; m/z MS (TOF ES+) 
C17H22N3O3 [MH]
+ calcd 316.2; found 316.2; LCMS tR: 3.63.
/	 ...'9$..'	(...
.	#$&		 	 tert
Butylisocyanate (0.063 mL, 0.55 mmol, 1.1 eq) was reacted as described in General Procedure 
A, to give 150 mg (91%) of offwhite foamy solid. 1H NMR (CDCl3) δ 7.94 – 7.89 (m, 1H), 7.73 
(d, J = 1.5 Hz, 1H), 7.70 – 7.64 (m, 2H), 7.49 – 7.41 (m, 2H), 6.47 (dd, J = 2.4/1.9 Hz, 1H), 5.49 
(s, 1H), 3.73 (s, 3H), 3.39 (s, 2H), 1.32 (s, 9H); 13C NMR (CDCl3) δ 172.1, 156.3, 141.1, 139.9, 
135.9, 128.5, 127.3, 119.9, 108.1, 77.5, 77.4, 77.2, 76.8, 56.7, 53.1, 51.2, 29.5; m/z MS (TOF 
ES+) C17H23N4O3 [MH]
+ calcd 331.2; found 331.2; LCMS tR: 3.57.
/	 ...'9$..'	(..	(9#$&		 , Benzoyl chloride 
(0.064 mL, 0.55 mmol, 1.1 eq) was reacted as described in General Procedure A, to give 166 mg 
(99%) of offwhite solid. 1H NMR (CDCl3) δ 7.92 (d, J = 2.2 Hz, 1H), 7.87 – 7.80 (m, 2H), 7.75 
(d, J = 1.5 Hz, 1H), 7.74 – 7.69 (m, 2H), 7.59 – 7.50 (m, 3H), 7.49 – 7.41 (m, 2H), 6.49 (dd, J = 
2.4/1.9 Hz, 1H), 5.81 (d, J = 6.7 Hz, 1H), 3.79 (s, 3H), 2.34 (s, 1H); 13C NMR (CDCl3) δ 171.4, 
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 166.7, 141.2, 140.1, 135.2, 133.6, 132.2, 128.8, 128.7, 127.3, 127.2, 119.9, 108.1, 56.4, 53.3; m/z 
MS (TOF ES+) C19H18N3O3 [MH]
+ calcd 336.1; found 336.1; LCMS tR: 3.62.
/	 ...'9$..'	(...,$$	(9#$&		  2
Fluorobenzoyl chloride (0.066 mL, 0.55 mmol, 1.1 eq) was reacted as described in General 
Procedure A. The reaction was complete within 90 min, and after workup, gave 186 mg of off
white solid (quantitative).1H NMR (CDCl3) δ 8.07 (ddd, J = 7.9/7.9/1.8 Hz, 1H), 7.92 (dd, J = 
2.5/0.5 Hz, 1H), 7.89 (dd, J = 6.9/6.3 Hz, 1H), 7.75 (d, J = 1.5 Hz, 1H), 7.74 – 7.69 (m, 2H), 
7.60 – 7.54 (m, 2H), 7.50 (dddd, J = 8.3/7.3/5.2/1.9 Hz, 1H), 7.28 – 7.23 (m, 1H), 7.16 (ddd, J = 
12.1/8.3/0.9 Hz, 1H), 6.49 (dd, J = 2.4/1.9 Hz, 1H), 5.81 (dd, J = 6.4/1.8 Hz, 1H), 3.79 (s, 3H), 
2.09 (s, 1H); 19F NMR (376 MHz, CDCl3) δ 112.78; 
13C NMR (CDCl3) δ 171.1, 167.0, 161.1 
(d, JCF = 248.2 Hz), 141.4, 140.4, 134.8, 134.0 (d, JCF = 9.4 Hz), 132.2 (d, JCF = 1.9 Hz), 128.7, 
126.9, 125.0 (d, JCF = 3.2 Hz), 124.8, 119.8, 116.3 (d, JCF = 24.7 Hz), 108.0, 56.8, 53.2; m/z MS 
(TOF ES+) C19H17FN3O3 [MH]
+ calcd 354.1; found 354.2; LCMS tR: 3.68.
/	 ...'9$..'	(...,$$	(9#$&		  3
Fluorobenzoic acid (74 mg, 0.53 mmol, 1.05 eq) and HCTU (228 mg, 0.55 mmol, 1.1 eq) were 
dissolved in DMF (0.5 mL) at room temperature. DIPEA (0.193 mL, 1.10 mmol, 2.2 eq) were 
added, followed by methyl 2(4(1Hpyrazol1yl)phenyl)2aminoacetate hydrochloride 
(134 mg, 0.50 mmol) and DCM (0.5 mL). The mixture was stirred at room temperature for 135 
min, before LCMS analysis indicated complete conversion had taken place. Sat. NaHCO3 
(aq)/water (1:1) (20 mL) was added, and the aqueous slurry extracted with Et2O (3 x 10 mL). The 
combined organic layers were washed with brine (10 mL), before concentrating under reduced 
pressure to give 189 mg (100%) pale brown solid, which was used without further purification. 
1H NMR (CDCl3) δ 7.92 (d, J = 2.2 Hz, 1H), 7.74 (d, J = 1.5 Hz, 1H), 7.73 – 7.69 (m, 2H), 7.65 
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 – 7.50 (m, 4H), 7.43 (ddd, J = 8.0/8.0/5.5 Hz, 1H), 7.23 (dddd, J = 8.3/8.3/ 2.6/1.0 Hz, 2H), 6.48 
(dd, J = 2.4/1.9 Hz, 1H), 5.78 (d, J = 6.7 Hz, 1H), 3.80 (s, 3H), 2.20 (s, 1H); 19F NMR (376 
MHz, CDCl3) δ 111.49; 
13C NMR (CDCl3) δ 171.2, 164.2, 164.0 (d, JCF = 279.3 Hz), 141.1, 
140.0, 135.9, 135.1, 130.5 (d, JCF = 7.9 Hz), 128.7, 127.3, 122.7 (d, JCF = 3.1 Hz), 120.0, 119.2 
(d, JCF = 21.2 Hz), 114.8 (d, JCF = 23.0 Hz), 108.1, 56.5, 53.4; m/z MS (TOF ES
+) C19H17FN3O3 
[MH]+ calcd 354.1; found 354.2; LCMS tR: 3.66.
/	 ...'9$..'	(...,$$	(9#$&		  4
Fluorobenzoic acid (74 mg, 0.53 mmol, 1.05 eq) was coupled to methyl 2(4(1Hpyrazol1
yl)phenyl)2aminoacetate hydrochloride (134 mg, 0.50 mmol) according to the procedure 
described for the synthesis of methyl 2(4(1Hpyrazol1yl)phenyl)2(3
fluorobenzamido)acetate , to give 214 mg (100%) of pale brown solid, which was used 
without further purification. 1H NMR (CDCl3) δ 7.94 – 7.91 (m, 1H), 7.88 – 7.81 (m, 2H), 7.74 
(d, J = 1.7 Hz, 1H), 7.73 – 7.68 (m, 2H), 7.57 – 7.51 (m, 2H), 7.16 – 7.09 (m, 2H), 6.58 – 6.33 
(m, 1H), 5.78 (d, J = 6.7 Hz, 1H), 3.79 (s, 3H), 2.27 (s, 1H); 19F NMR (376 MHz, CDCl3) δ 
107.24; 13C NMR (CDCl3) δ 171.4, 165.6, 165.3 (d, JCF = 284.8 Hz), 141.4, 138.9, 135.0, 131.9, 
129.7 (d, JCF = 9.0 Hz), 128.7, 127.0, 119.9, 115.9 (d, JCF = 22.0 Hz), 108.1, 56.5, 53.3; m/z MS 
(TOF ES+) C19H17FN3O3 [MH]
+ calcd 354.1; found 354.2; LCMS tR: 3.64.
/	 ...'9$..'	(...($	(9#$&		   3
Nitrobenzoyl chloride (102 mg, 0.55 mmol, 1.1 eq) was reacted as described in General 
Procedure A. After 4 h, further 3nitrobenzoyl chloride (27 mg, 0.3 eq) and TEA (0.035 mL, 0.5 
eq) were added and stirring continued for 24 h. LCMS analysis indicated incomplete conversion, 
so 3nitrobenzoyl chloride (46 mg, 0.5 eq) and TEA (0.035 mL, 0.5 eq) were added again and 
stirring continued for a further 24 h prior to workup, to give 188 mg (99%) pink solid. 1H NMR 
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 (CDCl3) δ 8.66 (dd, J = 1.9/1.9 Hz, 1H), 8.39 (ddd, J = 8.2/2.2/1.0 Hz, 1H), 8.22 – 8.15 (m, 1H), 
7.93 (dd, J = 2.5/0.4 Hz, 1H), 7.77 – 7.71 (m, 3H), 7.67 (dd, J = 7.9/7.9 Hz, 1H), 7.58 – 7.51 (m, 
2H), 7.37 (d, J = 6.0 Hz, 1H), 6.49 (dd, J = 2.4/1.9 Hz, 1H), 5.80 (d, J = 6.7 Hz, 1H), 3.81 (s, 
3H); 13C NMR (CDCl3) δ 171.1, 164.3, 148.4, 141.3, 140.2, 135.2, 134.6, 133.3, 130.1, 128.8, 
127.2, 126.7, 122.3, 120.0, 108.2, 77.5, 77.4, 77.2, 76.8, 56.7, 53.5; m/z MS (TOF ES+) 
C19H17N4O5 [MH]
+ calcd 381.1; found 381.2; LCMS tR: 3.66.
/	 ...'9$..'	(...($	(9#$&		 ! 4
Nitrobenzoyl chloride (102 mg, 0.55 mmol, 1.1 eq) was reacted as described in General 
Procedure A. After 4 h, an additional amount of 4nitrobenzoyl chloride (27 mg, 0.3 eq) and 
TEA (0.035 mL, 0.5 eq) were added and stirring continued for 24 h prior to workup. In this case, 
the mixture was diluted with EtOAc (20 mL), then washed with water (10 mL) and sat. NaHCO3 
(aq) (10 mL). The organic layers were concentrated under reduced pressure, to give 162 mg (85%) 
pink solid. 1H NMR (CDCl3) δ 8.36 – 8.28 (m, 2H), 8.05 – 7.96 (m, 2H), 7.93 (d, J = 2.4 Hz, 
1H), 7.78 (d, J = 1.7 Hz, 1H), 7.74 (d, J = 8.6 Hz, 2H), 7.55 (d, J = 8.5 Hz, 2H), 6.56 – 6.46 (m, 
1H), 5.79 (d, J = 6.6 Hz, 1H), 3.81 (s, 3H); 13C NMR (CDCl3) δ 171.2, 165.6, 150.0, 141.5, 
139.1, 137.4, 135.0, 128.7, 128.6, 127.0, 124.1, 119.9, 108.2, 56.7, 53.5; m/z MS (TOF ES+) 
C19H17N4O5 [MH]
+ calcd 381.1; found 381.2; LCMS tR: 3.65.
/	...'9$..'	(...($	(9#$&		 Methyl 2
(4(1Hpyrazol1yl)phenyl)2(3nitrobenzamido)acetate   (115 mg, 0.30 mmol) was 
dispersed in MeOH (20 mL) and 10% Pd/C (10 mg) added under an atmosphere of nitrogen. The 
reaction flask was sealed, before evacuating and replacement of the atmosphere with hydrogen. 
The mixture was then stirred under an atmosphere of hydrogen (balloon) for 1 h at room 
temperature. LCMS analysis after this time indicated that complete conversion had taken place, 
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 so the mixture was filtered through a bed of Celite with washings of MeOH. The filtrate was 
concentrated under reduced pressure to give 102 mg (97%) of offwhite glassy solid, which was 
used without further purification. 1H NMR (CDCl3) δ 7.89 (d, J = 1.8 Hz, 1H), 7.70 (s, 1H), 7.66 
(d, J = 8.4 Hz, 2H), 7.49 (d, J = 8.3 Hz, 2H), 7.42 – 7.30 (m, 1H), 7.23 – 7.04 (m, 3H), 6.81 (s, 
1H), 6.44 (s, 1H), 5.76 (d, J = 6.8 Hz, 1H), 4.16 – 3.53 (m, 5H); 13C NMR (CDCl3) δ 171.4, 
167.1, 147.0, 141.4, 140.3, 134.8, 134.6, 129.6, 128.6, 126.9, 119.6, 118.5, 116.7, 113.9, 107.9, 
56.4, 53.1; m/z MS (TOF ES+) C19H19N4O3 [MH]
+ calcd 351.1; found 351.2; LCMS tR: 3.37.
/	 ...'9$..'	(...($	(9#$&		  Methyl 
2(4(1Hpyrazol1yl)phenyl)2(4nitrobenzamido)acetate ! (62 mg, 0.16 mmol) was 
hydrogenated according to the procedure described for the synthesis of methyl 2(4(1Hpyrazol
1yl)phenyl)2(3aminobenzamido)acetate , to give 51 mg (91%) of brown solid. 1H NMR 
(CDCl3) δ 8.85 – 7.06 (m, 11H), 6.97 – 6.21 (m, 3H), 5.82 (s, 1H), 3.85 (s, 3H); 
13C NMR 
(CDCl3) δ 171.6, 166.5, 150.3, 141.4, 140.2, 135.1, 129.1, 128.6, 126.9, 122.7, 119.6, 114.2, 
107.9, 56.3, 53.1; m/z MS (TOF ES+) C19H19N4O3 [MH]
+ calcd 351.1; found 351.2; LCMS tR: 
3.42.
...89$..'	(..&	#$..#$%&	#	  Methyl 2(4
(1Hpyrazol1yl)phenyl)2acetamidoacetate  (120 mg, 0.44 mmol) was converted to the 
corresponding hydroxamic acid according to General Procedure B. The reaction was complete 
after 30 min. After purification, 69 mg (57%) of offwhite solid was obtained. 1H NMR (DMSO) 
δ 11.01 (s, 1H), 9.01 (s, 1H), 8.69 (d, J = 8.4 Hz, 1H), 8.58 – 8.27 (m, 1H), 7.90 – 7.76 (m, 2H), 
7.73 (d, J = 1.4 Hz, 1H), 7.49 (d, J = 8.6 Hz, 2H), 6.54 (dd, J = 2.4/1.8 Hz, 1H), 5.40 (d, J = 8.4 
Hz, 1H), 1.91 (s, 3H); 13C NMR (DMSO) δ 169.0, 166.6, 141.0, 139.1, 136.8, 128.1, 127.8, 
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 118.3, 107.9, 53.2, 22.4; m/z MS (TOF ES+) C13H15N4O3 [MH]
+ calcd 275.1; found 275.2; LC
MS tR: 3.07.
....89$..'	(..#$%($..$%$	'$'$(#	
Methyl 2(4(1Hpyrazol1yl)phenyl)2propionamidoacetate  (126 mg, 0.44 mmol) was 
converted to the corresponding hydroxamic acid according to General Procedure B. The reaction 
was complete after 4 h. After purification 44 mg (35%) of offwhite solid was obtained. 1H NMR 
(DMSO) δ 11.01 (d, J = 1.2 Hz, 1H), 9.02 (d, J = 1.3 Hz, 1H), 8.60 (d, J = 8.4 Hz, 1H), 8.47 (d, J 
= 2.1 Hz, 1H), 7.89 – 7.76 (m, 2H), 7.73 (d, J = 1.5 Hz, 1H), 7.50 (d, J = 8.6 Hz, 2H), 6.54 (dd, J 
= 2.4/1.8 Hz, 1H), 5.41 (d, J = 8.4 Hz, 1H), 2.22 (q, J = 7.5 Hz, 2H), 0.98 (t, J = 7.6 Hz, 3H); 13C 
NMR (DMSO) δ 172.7, 166.6, 141.0, 139.0, 136.8, 128.1, 127.8, 118.3, 107.9, 53.1, 28.0, 9.83; 
m/z MS (TOF ES+) C14H17N4O3 [MH]
+ calcd 289.1; found 289.2; LCMS tR: 3.14.
....89$..'	(..#$%($..$%$	$#	
&Methyl 2(4(1Hpyrazol1yl)phenyl)2isobutyramidoacetate& (122 mg, 0.40 mmol) 
was converted to the corresponding hydroxamic acid according to General Procedure B. After 22 
h of stirring, only partial conversion had occurred, so NH2OH.HCl (70 mg, 1 mmol) and 5M 
KOH/MeOH (0.5 mL, 2.5 mmol) were added and stirring continued at room temperature for a 
further 24 h. After purification, 71 mg (59%) of offwhite solid was obtained. 1H NMR (DMSO) 
δ 11.01 (d, J = 1.2 Hz, 1H), 9.03 (d, J = 1.3 Hz, 1H), 8.56 (d, J = 8.5 Hz, 1H), 8.51 – 8.43 (m, 
1H), 7.88 – 7.77 (m, 2H), 7.73 (d, J = 1.6 Hz, 1H), 7.50 (d, J = 8.6 Hz, 2H), 6.54 (dd, J = 2.4/1.8 
Hz, 1H), 5.40 (d, J = 8.4 Hz, 1H), 2.64 (hept, J = 6.8 Hz, 1H), 1.00 (d, J = 6.8 Hz, 3H), 0.97 (d, J 
= 6.8 Hz, 3H); 13C NMR (DMSO) δ 175.9, 166.6, 141.0, 139.0, 136.9, 128.0, 127.8, 118.3, 
107.9, 52.9, 33.3, 19.6, 19.5; m/z MS (TOF ES+) C15H19N4O3 [MH]
+ calcd 303.1; found 303.2; 
LCMS tR: 3.22.
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 ....89$..'	(..#$%($..$%$	'+#	 #
Methyl 2(4(1Hpyrazol1yl)phenyl)2pivalamidoacetate # (143 mg, 0.46 mmol) was 
converted to the corresponding hydroxamic acid according to General Procedure B. After 22 h of 
stirring, only partial conversion had occurred, so NH2OH.HCl (70 mg, 1 mmol) and 5M 
KOH/MeOH (0.5 mL, 2.5 mmol) were added and stirring continued at room temperature for a 
further 24 h. At this point additional NH2OH.HCl (139 mg, 2 mmol) and 5M KOH/MeOH (0.6 
mL, 3.0 mmol) were added and stirring continued for a further 24 h. After purification, 100 mg 
(68%) of glassy solid was obtained; 1H NMR (DMSO) δ 11.02 (s, 1H), 9.08 (s, 1H), 8.47 (d, J = 
2.4 Hz, 1H), 7.84 – 7.75 (m, 2H), 7.73 (d, J = 1.4 Hz, 1H), 7.51 (d, J = 8.6 Hz, 2H), 6.74 – 6.38 
(m, 1H), 5.41 (d, J = 8.1 Hz, 1H), 1.15 (s, J = 8.2 Hz, 9H); 13C NMR (DMSO) δ 176.9, 166.6, 
141.0, 139.0, 136.9, 127.9, 127.8, 118.3, 107.9, 53.2, 38.2, 27.2; m/z MS (TOF ES+) C16H21N4O3 
[MH]+ calcd 317.2; found 317.2; LCMS tR: 3.30.
...89$..'	(...
.	#$..#$%&	#	 	
Methyl 2(4(1Hpyrazol1yl)phenyl)2(3(tertbutyl)ureido)acetate	 (147 mg, 0.44 mmol) 
was converted to the corresponding hydroxamic acid according to General Procedure B. After 
4.5 h, starting material had disappeared by LCMS, with the formation of the desired product and 
corresponding carboxylic acid (hydrolysis product). After FCC purification (eluent MeOH/DCM 
0:100 to 10:90) the major product isolated was found to be 2(4(1Hpyrazol1yl)phenyl)2(3
(tertbutyl)ureido)acetic acid (44 mg, 32%). This was directly converted to the desired 
hydroxamic acid according to General Procedure D, using CDI (3 eq) and NH2OH.HCl (4 eq) 
and anhydrous THF (2 mL). After purification, 11 mg (8% based on ester, 24% based on acid) 
offwhite solid was obtained. 1H NMR (DMSO) δ 11.00 (s, 1H), 9.00 (s, 1H), 8.45 (d, J = 2.5 
Hz, 1H), 7.80 (d, J = 8.6 Hz, 2H), 7.73 (d, J = 1.6 Hz, 1H), 7.42 (d, J = 8.6 Hz, 2H), 6.65 (d, J = 
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 8.6 Hz, 1H), 6.59 – 6.46 (m, 1H), 6.12 (s, 1H), 5.18 (d, J = 8.6 Hz, 1H), 1.20 (s, 9H); 13C NMR 
(DMSO) δ 167.3, 156.2, 140.9, 138.9, 138.4, 127.7, 127.5, 118.3, 107.8, 53.3, 49.1, 29.2; m/z 
MS (TOF ES) C16H20N5O3 [MH]
 calcd 330.2; found 330.2; LCMS tR: 3.32.
....89$..'	(..#$%($..$%$		(9#	 ,
Methyl 2(4(1Hpyrazol1yl)phenyl)2benzamidoacetate , (161 mg, 0.48 mmol) was 
converted to the corresponding hydroxamic acid according to General Procedure B. After 22 h of 
stirring, only partial conversion had occurred, so NH2OH.HCl (70 mg, 1 mmol) and 5M 
KOH/MeOH (0.5 mL, 2.5 mmol) were added and stirring continued at room temperature for a 
further 24 h. At this point additional NH2OH.HCl (139 mg, 2 mmol) and 5M KOH/MeOH (0.6 
mL, 3.0 mmol) were added and stirring continued for a further 24 h. After FCC purification 
(eluent MeOH/DCM 0:100 to 10:90) the major product isolated was found to be 2(4(1H
pyrazol1yl)phenyl)2benzamidoacetic acid (99 mg, 65%). This was directly converted to the 
desired hydroxamic acid according to General Procedure D, using CDI (3 eq) and NH2OH.HCl 
(4 eq) and anhydrous THF (5 mL). After purification, 7 mg (4% based on ester, 7% based on 
acid) offwhite solid was obtained. 1H NMR (MeOD) δ 8.23 (dd, J = 2.5/0.4 Hz, 1H), 7.92 – 
7.85 (m, 2H), 7.81 – 7.70 (m, 3H), 7.68 – 7.61 (m, 2H), 7.60 – 7.51 (m, 1H), 7.51 – 7.41 (m, 
2H), 6.53 (dd, J = 2.5, 1.9 Hz, 1H), 5.68 (s, 1H); 13C NMR (MeOD) δ 169.9, 169.3, 142.3, 141.3, 
137.2, 135.0, 133.0, 129.9, 129.6, 129.1, 128.7, 120.5, 108.9, 56.2; m/z MS (TOF ES+) 
C18H17N4O3 [MH]
+ calcd 337.1; found 337.2; LCMS tR: 3.30.
....89$..'	(..#$%($..$%$	..,$$	(9#	
 Methyl 2(4(1Hpyrazol1yl)phenyl)2(2fluorobenzamido)acetate (168 mg, 0.48 
mmol) was converted to the corresponding hydroxamic acid according to General Procedure B. 
The reaction was complete after 2 h. After purification 100 mg (59%) of offwhite solid was 
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 obtained. 1H NMR (DMSO) δ 11.12 (d, J = 1.2 Hz, 1H), 9.14 (d, J = 1.3 Hz, 1H), 8.90 (dd, J = 
7.9/4.0 Hz, 1H), 8.54 – 8.39 (m, 1H), 7.91 – 7.77 (m, 2H), 7.74 (d, J = 1.4 Hz, 1H), 7.65 (ddd, J 
= 7.7/7.7/1.8 Hz, 1H), 7.62 – 7.49 (m, 3H), 7.35 – 7.24 (m, 2H), 6.54 (dd, J = 2.4/1.8 Hz, 1H), 
5.58 (d, J = 7.9 Hz, 1H); 19F NMR (376 MHz, DMSO) δ 113.8; 13C NMR (DMSO) δ 166.2, 
163.1, 159.3 (d, JCF = 205.6 Hz), 141.0, 139.2, 136.3, 132.9 (d, JCF = 8.5 Hz), 130.4 (d, JCF = 2.6 
Hz), 128.2, 127.8, 124.5 (d, JCF = 3.3 Hz), 121.7 (d, JCF = 30.4 Hz), 118.4, 116.1 (d, JCF = 22.8 
Hz), 107.9, 53.9; m/z MS (TOF ES) C18H14FN4O3 [MH]
 calcd 353.1; found 353.1; LCMS tR: 
3.41.
....89$..'	(..#$%($..$%$	..,$$	(9#	
Methyl 2(4(1Hpyrazol1yl)phenyl)2(3fluorobenzamido)acetate (172 mg, 0.49 
mmol) was converted to the corresponding hydroxamic acid according to General Procedure B. 
The reaction was complete after 2 h. After purification 101 mg (58%) of offwhite solid was 
obtained. 1H NMR (DMSO) δ 11.06 (d, J = 1.2 Hz, 1H), 9.11 (d, J = 8.0 Hz, 1H), 9.06 (d, J = 
1.3 Hz, 1H), 8.53 – 8.44 (m, 1H), 7.88 – 7.81 (m, 2H), 7.81 – 7.71 (m, 3H), 7.61 (d, J = 8.6 Hz, 
2H), 7.52 (ddd, J = 8.1/8.1/ 6.1 Hz, 1H), 7.45 – 7.35 (m, 1H), 6.55 (dd, J = 2.4/1.8 Hz, 1H), 5.63 
(d, J = 8.0 Hz, 1H); 19F NMR (376 MHz, DMSO) δ 113.1; 13C NMR (DMSO) δ 166.4, 165.0, 
164.2 (d, JCF = 225.0 Hz), 141.0, 139.2, 136.1 (d, JCF = 6.9 Hz), 136.0, 130.3 (d, JCF = 7.8 Hz), 
128.7, 127.8, 124.0 (d, JCF = 2.5 Hz), 118.4 (d, JCF = 21.3 Hz), 118.2, 114.6 (d, JCF = 23.1 Hz), 
107.9, 54.3; m/z MS (TOF ES+) C18H16FN4O3 [MH]
+ calcd 355.1; found 355.2; LCMS tR: 3.35.
....89$..'	(..#$%($..$%$	..,$$	(9#	
 Methyl 2(4(1Hpyrazol1yl)phenyl)2(4fluorobenzamido)acetate  (193 mg, 0.55 
mmol) was converted to the corresponding hydroxamic acid according to General Procedure B. 
The reaction was complete after overnight stirring. After purification 97 mg (50%) of offwhite 
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 solid was obtained. 1H NMR (DMSO) δ 11.05 (s, 1H), 9.05 (s, 1H), 9.02 (d, J = 8.1 Hz, 1H), 
8.49 (d, J = 2.3 Hz, 1H), 8.09 – 7.90 (m, 2H), 7.83 (d, J = 8.7 Hz, 2H), 7.74 (d, J = 1.5 Hz, 1H), 
7.61 (d, J = 8.6 Hz, 2H), 7.36 – 7.23 (m, 2H), 6.63 – 6.47 (m, 1H), 5.63 (d, J = 8.0 Hz, 1H); 19F 
NMR (376 MHz, DMSO) δ 109.1; 13C NMR (DMSO) δ 167.0 (d, JCF = 230.6 Hz), 166.5, 
165.3, 141.0, 139.2, 136.2, 130.5 (d, JCF = 8.9 Hz), 130.3, 128.6, 127.8, 118.2, 115.1 (d, JCF = 
21.7 Hz), 108.1 – 107.6 (m), 54.3; m/z MS (TOF ES+) C18H16FN4O3 [MH]
+ calcd 355.1; found 
355.2; LCMS tR: 3.36.
....89$..'	(..#$%($..$%$	..($	(9#	
 Methyl 2(4(1Hpyrazol1yl)phenyl)2(3aminobenzamido)acetate  121 mg, 0.35 
mmol) was converted to the corresponding hydroxamic acid according to General Procedure C, 
to give 58 mg (47%) of offwhite solid. 1H NMR (DMSO) δ 11.03 (d, J = 0.9 Hz, 1H), 9.06 (d, J 
= 1.2 Hz, 1H), 8.53 (d, J = 8.1 Hz, 1H), 8.48 (d, J = 2.4 Hz, 1H), 7.82 (d, J = 8.7 Hz, 2H), 7.74 
(d, J = 1.5 Hz, 1H), 7.60 (d, J = 8.6 Hz, 2H), 7.17 – 6.91 (m, 3H), 6.70 (ddd, J = 7.6/2.2/1.2 Hz, 
1H), 6.62 – 6.45 (m, 1H), 5.59 (d, J = 8.1 Hz, 1H), 5.25 (s, 2H); 13C NMR (DMSO) δ 166.8, 
166.6, 148.7, 141.0, 139.1, 136.5, 134.6, 128.7, 128.4, 127.8, 118.3, 116.7, 114.8, 113.0, 107.9, 
53.9; m/z MS (TOF ES+) C18H18N5O3 [MH]
+ calcd 352.1; found 352.2; LCMS tR: 3.14.
....89$..'	(..#$%($..$%$	..($	(9#	
Methyl 2(4(1Hpyrazol1yl)phenyl)2(4aminobenzamido)acetate (46 mg, 0.13 
mmol) was converted to the corresponding hydroxamic acid according to General Procedure C, 
to give 20 mg (43%) of offwhite solid; 1H NMR (DMSO) δ 11.01 (s, 1H), 9.02 (s, 1H), 8.48 (d, 
J = 2.2 Hz, 1H), 8.31 (d, J = 8.2 Hz, 1H), 7.81 (d, J = 8.7 Hz, 2H), 7.73 (d, J = 1.5 Hz, 1H), 7.66 
(d, J = 8.7 Hz, 2H), 7.59 (d, J = 8.6 Hz, 2H), 6.65 – 6.39 (m, 3H), 5.67 (s, 2H), 5.60 (d, J = 8.2 
Hz, 1H); 13C NMR (DMSO) δ 166.9, 166.0, 152.0, 141.0, 139.1, 136.8, 129.3, 128.5, 127.8, 
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 120.2, 118.2, 112.5, 107.9, 53.8; m/z MS (TOF ES) C18H16N5O3 [MH]
 calcd 350.1; found 
350.1; LCMS tR: 3.19.
 
3$&	
8	'$( $, 	&$(( /-8 The production of recombinant malaria 
aminopeptidases in Escherichia coli and purification using a twostep purification process of Ni
NTAagarose column followed by size exclusion chromatography on a Superdex 200 16/60 
using a AKTAxpress high throughput chromatography system 
(http://proteinexpress.med.monash.eud.au/index.htm) was as described.7, 9 Biochemical analysis 
indicated that kinetic parameters (kcat, Km, kcat/Km) of material purified and used in subsequent 
crystallization trials were the same as published.7, 9  
=(9&-( Aminopeptidase activity of enzymes was determined by measuring 
the release of the fluorogenic leaving group, NHMec, from the fluorogenic peptide LLeucine7
amido4methylcoumarin hydrochloride (HLeuNHMec) (Sigma L2145). The assay protocol 
devised by Stack et al was modified and used.5 The reactions were carried out in 96well 
microtitre plates, 200 \l total volume at 37°C using a spectrofluorimeter (BMG FLUOstar) with 
excitation at 355nm and emission at 460 nm. PfAM1 was preincubated in 100 mM Tris pH 8.0 
at 37°C and PfAM17 in 50 mM Tris pH 8.0, 2 mM CoCl2, with the inhibitors for 10 min prior to 
the addition of substrate. Inhibitor concentrations were assayed between 0 – 500 \M. The 
fluorescence signal was monitored until a final steady state velocity, V, was obtained. The Ki 
values were then evaluated using Dixon plots of 1/V versus inhibitor concentration while the 
substrate concentration was maintained lower than that of the Km of the enzyme. 
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$((#>.6$	&$( Crystals of the PfAM1 bound complexes 
were obtained by cocrystallization of each compound with PfAM1 in mother liquor containing 
1 mM ligand. For PfAM17 bound complexes, prior to data collection, crystals were soaked in 
mother liquor containing 1 mM ligand and 1 mM ZnSO4. Data were collected at 100 K using 
synchrotron radiation at the Australian synchrotron using the macro crystallography MX1 
beamline 3BM1 for PfAM1 and the micro crystallography MX2 beamline 3ID1 for PfAM17. 
Diffraction images were processed using iMosflm, 55 XDS,56 pointless57, 58 and SCALA57 from 
the CCP4 suite.59 5% of each dataset was flagged for calculation of RFree 
60
 with neither a sigma 
nor a lowresolution cutoff applied to the data.  A summary of statistics is provided in 
)''		(	 .  Subsequent crystallographic and structural analysis was performed 
using the Phenix suite 61, 62. The inhibitor complex was initially solved and refined against the 
unbound PfAM1 and PfAM17 structures (protein atoms only) as described previously 7, 9, 13, 63, 
64 and clearly showed unbiased features in the active site for each structure. The coordinates and 
structure factors will be available from the Protein Data Bank (PDB Accession codes: 4R5T, 
4R5V, 4R5X, 4R6T, 4R76, 4R7M). Raw data and images will be available from TARDIS 
(https://store.synchrotron.org.au).65, 66 
/$	&6$&!( Molecular docking was carried out by means of Molegro Virtual 
Docker (MVD) software (® CLCbio). Ligands were built and energy minimized by using the 
PRODRG server.67 Flexible torsions were automatically detected by MVD, and manually 
checked for consistency. The obtained threedimensional structures of PfAM1 and PfAM17 
were prepared by automatically assigning bond orders and hybridization, and adding explicit 
hydrogens, charges and Tripos atom types. Missing heavy atoms were fixed by modeling them, 
using Modeler v.9.8 68 and PyMod.69 A search space of 12 Å radius, centered on 
, was used for 
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 docking. Side chain flexibility and displaceable waters were set for atoms at 5 Å or less from 
. 
The hydroxamic acid and NH of the Boc group of 
 were taken as electrostatic pharmacophoric 
groups for templatebased dockings. In this way, if an atom of the ligand matches a group 
definition (e.g. positively/negatively charged), it is rewarded by using a weighted score (w) that 
depends on its distance to the group centers, by using the following Gaussian function for each 
center:  
w = ω*exp(1d
2
/r0
2
)        (1) 
where d is the distance (Å) from the position of the atom to the center in the group. ω is a 
weight factor for the template group, and r0 is a distance parameter, specifying a characteristic 
distance for the template group. ω and r0 were set at ω = 2; r0 = 1.80. An overall normalization 
of the similarity score term, to balance it with other scoring terms, is then applied for each atom. 
Gridbased MolDock score70 with a grid resolution of 0.30 Å was used as scoring function for 
docking. MolDock SE was used as docking algorithm. For each ligand, ten runs were defined. 
Similar poses (RMSD < 1.2 Å) were clustered, and the best scoring one was taken as 
representative. Other docking parameters were fixed at their default values. After docking, 
energy optimization of hydrogen bonds was performed. 
 
3$$
	
&	 In vitro parasite culture of the P. falciparum strain 3D7 was maintained 
in RPMI with 10 mM Hepes (Life Technologies), 50 \g/mL hypoxanthine (Sigma) and 5 mg/mL 
AlbuMAX II® (Life Technologies). Human 0+ erythrocytes were obtained from the Australian 
Red Cross Blood Service (Agreement No: 1304QLD09). The parasites were maintained at 28 
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 % parasitaemia (% P) at 5 % haematocrit (% H), incubated at 37 °C, 5 % CO2, 5 % O2, 90 % N2 
and 95 % humidity. 
	
$5($( A wellestablished P. falciparum imaging assay 
was used to assess parasite growth inhibition 47. In brief, sorbitol (5% w/v) synchronisation was 
performed twice, approximately 8 h apart, on each synchronisation day for two consecutive ring 
cycles i.e. on day 1 and 3 of assay preparation. On day 2 the culture was split to approximately 2 
% trophozoite parasitaemia. On day 4 the culture was split to 11.5% trophozoite parasitaemia, 
which yielded approximately 8% ring parasitaemia after 48 h on day 5, the day of the assay 
setup. 
Compound stocks (10 mM in 100 % DMSO) were diluted 1 in 25 in sterile water, less 
than 24 h prior to use. An additional 1 in 10 dilution was performed, resulting in a 1:250 overall 
compound dilution and a final DMSO concentration of 0.4%. For dose response curves a three 
step logarithmic serial dilution in 4 % DMSO was prepared at 40 \M top concentration for test 
compounds and 2 \M for the positive control, artemisinin. Five \l of the diluted test compound 
or control solutions (20 \M artemisinin as positive and 4% DMSO as negative control) were 
added to 384 well CellCarrier imaging plates (PerkinElmer) for a final 1:10 dilution in parasite 
culture. The resulting final DMSO concentration for all sample dilutions and controls was 0.4%. 
Parasite culture was added to a final concentration of 2 % parasitemia and 0.3 % 
haematocrit. Plates were incubated for 72 h at 37 °C, 5 % CO2 and 95 % humidity. On day 8 the 
permeabilization and nuclear staining buffer was prepared in PBS containing10 \g/mL saponin, 
0.01% triton X, 5 mM EDTA (all: Sigma) and 0.5 \g/mL 4′,6diamidino2phenylindole (DAPI; 
Life Technologies).47 
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 The plates were incubated at RT overnight, before confocal imaging on an Opera™ 
Confocal Imager (PerkinElmer) at 405 nm excitation with a 20x water objective. Automated 
primary image analysis was performed concurrent with the imaging process, utilizing an 
Acapella® software (PerkinElmer) script to determine the number of parasites based on object 
size and fluorescence intensity.47 Determination of the % growth compared to controls (2 \M 
artemisinin as positive and 0.4% DMSO as negative control) was performed in Microsoft ® 
Excel 2010. Statistical analysis including IC50 determination and graphical output was performed 
in GraphPad Prism® 5 using nonlinear regression variable slope curve fitting. 
"=? +  To assess cytotoxicity of compounds in dose response, a 
resazurinbased assay was utilized to test for cell viability. In brief, HEK293 cells were grown in 
DMEM medium (Life Technologies) containing 10 % fetal calf serum (FCS; Gibco). Cells were 
trypsinised, counted and seeded at 2000 cells per well in 45 \L media into TCtreated 384well 
plates (Falcon) and left to adhere overnight at 37 °C, 5 % CO2 and 95 % humidity. 
Test compounds were prepared as described above, to give a top final test concentration 
of 40 \M, 0.4% DMSO. Plates were incubated for 72 h at 37 °C, 5% CO2 and 95 % humidity, 
then the media was removed and replaced by 35 \L of 44 \M resazurin in DMEM without FCS. 
The plates were incubated for another 46 h at 37 °C, 5 % CO2 and 95 % humidity, before 
reading on an EnVision® Plate Reader (PerkinElmer) using fluorescence excitation/emission 
settings of 530 nm/595 nm. Determination of the % growth compared to controls (40 \M 
puromycin as positive and 0.4 % DMSO as negative control) was performed in Microsoft® Excel 
2010. Statistical analysis including IC50 determination and graphical output was performed in 
GraphPad Prism® 5 using nonlinear regression variable slope curve fitting. 
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 ASSOCIATED CONTENT 
)''$( <(,$$(. Figures detailing compound docking (interactions of each 
compound for each model generated), representative compound electron density in crystal 
structures, and additional compound overlays. Crystallographic data collection and refinement 
statistics. This material is available free of charge at http://pubs.acs.org.
-&&	$($#	. PDB IDs: 4R5T, 4R5V, 4R5X, 2R6T, 4R76, 4R7M 
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hexafluorophosphate; PE, petroleum spirits 4060; TEA, triethylamine; ZBG, zincbinding 
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 	  Inhibition of PfAM1 and PfAM17 by novel hydroxamic acid derivatives . and
.. 
 
 4

 4


A/

 <B)6(/

-./ 
-./
 6

 Boc OH > 500 464  
 H.HCl OH > 500 > 500  

 Boc NHOH 0.8 0.03 783 ± 86.6 
 H.HCl NHOH 74.5 86  
 CH3(C=O) NHOH 113 0.019 619 ± 52.7 
 CH3CH2(C=O) NHOH 41.3 0.016 455 ± 60.9 
& (CH3)2CH(C=O) NHOH 12.3 0.053 532 ± 13.3 
#
tBu(C=O) NHOH 0.7 0.028 227 ± 4.24 
	
tBuNH(C=O) NHOH 15.3 0.038 597 ± 10.2 
, benzoyl NHOH 23 0.154  
 2fluorobenzoyl NHOH 1.9 0.008 351 ± 29.8 
 3fluorobenzoyl NHOH 4 0.035 429 ± 30.6 
 4fluorobenzoyl NHOH 11.2 0.012 703 ± 49.8 
 3aminobenzoyl NHOH 5.5 0.014 233 ± 124.8 
 4aminobenzoyl NHOH 7.4 0.011 228 ± 23.47 
a Ki values are calculated using Dixon plots of 1/V versus inhibitor concentration while the substrate concentration 
was maintained lower than that of the Kmof the enzyme. Dixon plots can be found in )''		(	 
b IC50 values were calculated against Plasmodium falciparum 3D7. See also )''		(	 
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 FIGURE LEGENDS 
 
	: ((4(1HPyrazol1yl)phenyl)(amino)methyl)phosphonic acid .13 
 
	7"#$%&&#&,,$#$5&$'$(#&&	$	)*'$&!	$,-./
(#-./
(- and 3)Stick representation of the binding mode of compound 
 (purple) to 
(-) PfAM1 (grey), and (3) PfAM17 (beige). Hydrogen bonds are shown as black dash, key 
hydrophobic interactions as orange dash, zinc ions as black spheres, and ordered water molecules 
as orange spheres. ( and 6) Overlay of the binding pose of dock (teal) and 
 (purple) in PfA
M1 () and PfAM17 (6). The boc group of 
 probes the S1’ pocket of both enzymes. Active 
site zinc and carbonate ions are indicated. (= and ) Overlay of the binding pose of 
 (purple) 
and  (blue) in PfAM1 (=) and PfAM17 (). The binding pose of compound 
 is dictated by 
the hydroxamic acid ZBG rather than the 4(1Hpyrazol1yl)phenyl moiety. 
 
	7)&(+	$($,	)*'$&!	$,-./(#-./
 (-) Overlay of 
the binding pose of 
 (purple) and # (orange) to PfAM1 (grey). PfAM1 has an enantiomeric 
preference for S
, and R#, which allows the tertbutyl groups of both compounds to occupy 
similar space and interact with Val493. (3) Overlay of the binding pose of 
 (purple) and #dock 
(orange) to PfAM17 (beige). Similarly to PfAM1, PfAM17 has an enantiomeric preference for 
S
, and R#, however formation of a hydrogen bond between Gly489 (black dash) directs the 
branched alkanes (tertbutyl in #) out of the hydrophobic S1’ cavity. () Binding mode of 
compound  (green) to PfAM1. Hydrogen bonds are shown as black dash, zinc ion as black 
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 sphere, and ordered water molecules as red spheres. (6) Binding pose of 13l (green) and 13m 
(grey) in the PfAM17 cavity. The pocket is flanked of hydrophilic residues at the neck (shown 
in stick representation), and a small hydrophobic auxiliary cavity off the S1’ pocket is visible. 
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FIGURE 1 
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 FIGURE 2 
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 FIGURE 3 
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 )&		  Synthesis of carbonyl derivatives of ((4(1Hpyrazol1
yl)phenyl)(amino)methyl)phosphonic acid (). 

a Reagents and conditions: (a) pyrazole, Cs2CO3, Cu2O, DMF, 100°C, 97%; (b) SeO2, 
anhydrous pyridine, 110°C, 92%; (c) N,N1dibenzylamine, Na(OAc)3BH, 1,2dichloroethane, rt; 
(d) H2, 10% Pd/C, conc. HCl, MeOH, water, rt; (e) NaHCO3(aq), Boc2O, THF, rt, 56% (over 3 
steps); (f) 4M HCl/14,dioxane, DCM, rt, 2597%; (g) i. CDI, THF, rt; ii. NH2OH.HCl, rt, 69%. 
  
Page 63 of 65
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 )&		Synthesis of amide and urea analogues of tertbutyl (1(4(1Hpyrazol1yl)phenyl)
2(hydroxyamino)2oxoethyl)carbamate (
). 

a Reagents and conditions: (a) i. Benzylamine, anhydrous 1,2dichloroethane, rt; ii. 
Na(OAc)3BH, rt, 76%; (b) conc. H2SO4, MeOH, reflux, 89%; (c) i. H2 (balloon), 10% Pd/C, 
conc. HCl, MeOH; ii. Sat. NaHCO3 workup; iii. 1M HCl/Et2O, Et2O, DCM, 87%; (d) i. TEA, 
DCM; ii. acid chloride or isocyanate, 8599%; (e) substituted benzoic acid, HCTU, DIPEA, 
DCM, DMF, rt, 100%; (f) 10% Pd/C, MeOH, rt, 9197%; (g) i. NH2OH.HCl, MeOH, rt; ii. 
KOH/MeOH, 3568%; (h) i. NH2OH.HCl, MeOH, rt; ii. KOH/MeOH; iii. FCC purification to 
isolate acid; iv. CDI, dry THF, rt; v. NH2OH.HCl, 48%; (i) i. dry MeOH, rt; ii. NH2OH.HCl, 
5M KOH/MeOH, dry MeOH (premixed), 4347%. 

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